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Multiple sclerosis (MS) is a disabling disorder of the central nervous system (CNS) 
characterized by motor, visual, and sensory deficits.  It is believed to be an autoimmune process 
in which immune cells infiltrate the brain and spinal cord leading to demyelination and cell 
death.  Myeloid cells, such as macrophages and dendritic cells, are a major component of the 
cellular infiltrates in the CNS.  Initial studies described these myeloid cells as pathogenic, but 
recent evidence in other systems has revealed that myeloid cells may also be anti-inflammatory 
and even pro-regenerative.  Little is known about the heterogeneity of myeloid cells in MS.  We 
set out to investigate the diverse phenotypes and functional properties of myeloid cells in CNS 
autoimmunity.   
Pro-inflammatory and anti-inflammatory myeloid cells have been termed classically or 
alternatively activated myeloid cells (CAMC, AAMC), respectively.  We began by identifying 
markers of CAMC and AAMC in MS lesions.  We observed a spectrum of activation such that 
CAMC were present at the active lesion rim while AAMC were predominant in the relatively 
quiescent lesion core.  Using the animal model experimental autoimmune encephalomyelitis, we 
identified similar CAMC and AAMC in the CNS with the markers iNOS and Arg1, respectively.  
Myeloid cell phenotypes evolved such that iNOS+ CAMC were present early in disease while 
Arg1+ AAMC were present at peak and late disease.  We further demonstrated that individual 
cells were plastic and shifted from expression of iNOS to Arg1 over the course of disease.   
One function of myeloid cells is the activation of T cells.  Activation is critical for the 
initiation of disease.  We compared the functional properties of Arg1+ and Arg1- cells and found 
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that Arg1+ cells were deficient in activating CD4+ T cells compared with Arg1- cells.  
Investigation of the mechanism of this defect led to the elucidation of additional myeloid cell 
subsets.  We identified that the dendritic cell population was heterogenous, not only in activation 
state or phenotype, but also in developmental lineage.  We identified cells of both the 
conventional (cDC) and monocyte-derived dendritic cell (moDC) lineages in the CNS during 
EAE and demonstrated functional specialization between these subsets.  iNOS and Arg1 
expression were restricted to the moDC subset, and this subset as a whole was deficient in T cell 
activation but proficient in phagocytosis.  Conversely, cDC were highly efficient in activating T 
cells but weak phagocytes. 
It is not clear which antigen presenting cell activates T cells to initiate disease.  We 
observed that cDC were present in the naïve brain and meninges and that these cells from the 
naïve CNS could activate myelin-specific T cells.  We further demonstrated that specific 
depletion of cDC reduces the incidence of EAE.  This identifies cDC as critical antigen 
presenting cells for the initiation of CNS autoimmunity.  Together, these studies clarify the 
diversity of myeloid cells and demonstrate functional differences with implications for clinical 
disease.  The results presented herein provide a foundation for the development of myeloid cell-




Chapter 1 - Introduction 
 
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS) which causes 
debilitating motor, visual, and sensory deficits.  It is a leading cause of disability in young adults 
and affects ~400,000 individuals in the United States1 and over 2.3 million worldwide2.  Patients 
are typically diagnosed between 20 and 40 years of age, and MS can have a devastating impact 
on their quality of life.  Patients with MS are 3.3-fold more likely to not be employed, lose an 
average of 10 quality adjusted life years3, and have life expectancy reduced by 7-14 years4.  MS 
is also the second most costly chronic condition in the United States, with costs ranging from 
$8,528-$54,244 per patient per year5.  MS carries significant personal and financial costs, and 
while current treatments offer hope, there is great need for new therapies which can prevent and 
even reverse the pathology of MS. 
 
Epidemiology of MS 
MS patients follow one of four different clinical courses: relapsing-remitting (RRMS), 
secondary progressive (SPMS), primary progressive (PPMS), or progressive-relapsing (PRMS)6.  
85% of patients have a relapsing-remitting course at onset in which bouts of disability may 
persist for weeks or months but resolve7,8.  Within 10 years, half of patients with RRMS will 
advance to a secondary progressive course which is characterized by increasing disability 
without a return to baseline.  Another 10% of patients are diagnosed with primary progressive 
disease characterized by gradual accumulation of disability without distinct relapses and 
remissions.  The rarest form is progressive-relapsing MS which affects ~5% of MS patients.  In 
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this course, patients experience distinct relapses and remissions superimposed on a progressive 
increase in disability such that attacks leave permanent deficits without a return to baseline.  It is 
currently unclear whether these clinical courses are distinct or whether they represent different 
stages or presentations of a fundamental similar inflammatory process.   
The etiology of MS is uncertain but both genetic and environmental factors may 
contribute.  Pointing to a role for genetics, the risk for first degree relatives is 20 times higher 
than the general population, and several susceptibility genes have been identified including genes 
in the MHC loci and those related to T cell function9. However, genes are not the only factor as 
the prevelance in monozyogotic twins is only 20%.  Environment also plays a role.  For example, 
incidence is higher in northern latitudes10, for those with low levels of Vitamin D11, or with past 
infection with Epstein Barr virus12,13.   
 
Pathogenesis of MS 
A pathologic feature of MS is damage of the myelin which insulates nerve axons in the 
brain and spinal cord14.  The CNS lesions were first described by Jean Cruveilhier and Robert 
Carswell in the 1830s followed by Jean-Martin Charcot in 186815.  Charcot was the first to 
connect these pathologic lesions with clinical findings and to identify MS as a distinct disease.  
Histological examination of lesions in the CNS reveal demyelination, blood-brain barrier 
breakdown, axonal degeneration, and reactive gliosis.  Lesions are infiltrated by peripheral 
immune cells including T lymphocytes and macrophages and can be classified by the degree of 
demyelination and inflammation16.  Active lesions are characterized by loss of myelin with 
diffuse infiltration of the complete lesion area with macrophages and microglia; inactive lesions 
are similarly demyelinated but hypocellular with few macrophages17.  An intermediate 
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phenotype has also been observed with macrophages localized to the active lesion rim but absent 
in the quiescent lesion center.  MS disease progression correlates with a shift in predominance of 
active to mixed to inactive lesions demonstrating the evolution of neuroinflammation over the 
course of disease18.   
Given the central role of the immune system in the CNS pathology, MS is believed to be 
autoimmune, and several disease-modifying therapies have been developed to target the immune 
system.  To date, 15 drugs have been approved by the FDA for the treatment of MS, and though 
the specific mode of action for many are still under investigation, the drugs can generally be 
grouped by proposed mechanism19.  Daclizumab, alemtuzumab, and ocrelizumab are monoclonal 
antibodies which target specific leukocyte subsets for depletion.  Fingolimod and natalizumab 
block immune cell release for the lymph nodes or access to the CNS, respectively, and 
teriflunomide targets proliferating lymphocytes.  IFNβ, glatiramer acetate, and dimethyl 
fumarate are believed to shift the quality of the immune response from pro- to anti-inflammatory. 
These therapies have proved to be effective at reducing the relapse rate in RRMS, 
highlighting the critical role for inflammation in the pathology of MS.  However, few show 
efficacy in the progressive stage of disease and none reverse disability or promote recovery20.  
There is a significant gap in this therapeutic arsenal in that none of the approved therapies 
specifically target myeloid cells.  These are cells of the innate immune system which are derived 
from common myeloid precursors in the bone marrow and include monocytes, macrophages, 
dendritic cells, neutrophils, basophils, eosinophils, erythrocytes, and megakaryocytes.  
Monocytes, macrophages, and dendritic cells, in particular, are prominent populations in MS 
lesions and are key effectors in the pathologic process by breaking down and phagocytosing 
myelin.  Several recent studies have also demonstrated that myeloid cells may be dysregulated 
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specifically in progressive stages of disease21–24.  But while the pathologic role of myeloid cells 
is clear, there is a growing body of evidence that differentially activated myeloid cells may be 
anti-inflammatory or even pro-regenerative.  
 
Myeloid cell phenotypes in vitro 
Myeloid cells acquire different phenotypes in response to different environmental cues.  
In the 1980s, Nathan and colleagues first demonstrated that macrophages activated by 
stimulation with IFNγ have enhanced cytotoxic properties25.  In the 1990s, Stein, Doyle, and 
colleagues noted that IL-4 and IL-13 also activated macrophages, but these activated 
macrophages differed from those stimulated by IFNγ by reduced secretion of pro-inflammatory 
cytokine and enhanced expression of the mannose receptor26,27.   In 2000, Mills and colleagues 
further characterized these as classically or alternatively activated macrophages and assigned the 
names M1 and M2, respectively, given their association with cytokines produced by Th1 or Th2 
cells28.  M1 macrophages were generated by stimulation with IFNγ and identified by expression 
of the enzyme inducible nitric oxide synthase (iNOS); M2 macrophages were generated in 
response to IL-4 and identified by expression of the enzyme arginase-1 (Arg1) (Figure 1.1).   
 
Figure 1.1 – In vitro macrophage polarizations. 
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M1 and M2 macrophages have a different impact on inflammatory response.  M1 
macrophages produce cytokines such IL-1β, IL-6, and TNFα to promote ongoing inflammation 
while M2 macrophage produce IL-10 and TGFβ1 to tamp down to the inflammatory response29.  
Even their canonical enzymes have distinct effects.  Both iNOS and Arg1 metabolize the amino 
acid arginine but generate different products.  iNOS generates toxic nitric oxide radicals while 
Arg1 generates trophic polyamines30,31.  Given their influence on the inflammatory response, M1 
macrophages were characterized as “pro-inflammatory” and M2 macrophages were 
characterized as “anti-inflammatory”.  
While the M1/M2 nomenclature provided a framework to understand macrophage 
activation, it quickly became clear that this framework was incomplete as additional cytokines 
and factors were shown to influence macrophage polarization.  To address this, new subsets were 
proposed including IL-4-stimulated M2a, immune complex-stimulated M2b, and IL-10-
stimulated M2c32.  Further study also revealed that polarization of macrophages is not fixed.  For 
example, macrophages stimulated with IFNγ to induce iNOS expression can be converted to 
produce Arg1 by secondary stimulation with IL-4, and vice versa33.  It is unclear, however, 
whether this represents a reprogramming of individual cells or an expansion of different cells 
within a heterogenous population. 
 
Myeloid cell phenotypes in vivo 
In the complex inflammatory milieu in vivo, macrophages exist in a spectrum of 
phenotypes.  The markers and functional attributes of these myeloid cells are highly dependent 
on the tissue and disease model.  For example, macrophages present early in the response to 
neoplasia are similar to classically-activated, pro-inflammatory myeloid cells and can be 
6 
 
protective by eradicating transformed cells34,35, but as tumors grow, an anti-inflammatory 
macrophage population develops.  These cells are often described as tumour-associated 
macrophages and can be anti-inflammatory by secreting high amounts of IL-1036.  As an 
alternative example, macrophages in non-obese adipose tissue appear anti-inflammatory with 
low expression of cytokines and high expression of Arg1.  However in obesity, adipose 
macrophages begin to produce pro-inflammatory cytokines such as TNFα and IL-6 which 
fundamentally alter the inflammatory milieu37.  A similar shift from anti- to pro-inflammatory 
macrophages has been observed in atherosclerosis37.  The phenotypes of myeloid cells in disease 
can have critical influence on the inflammatory process, and thus extensive study is necessary to 
understand the properties and functions of myeloid cells in a manner specific to tissue and 
disease process. 
 
Experimental autoimmune encephalomyelitis 
The animal model experimental autoimmune encephalomyelitis (EAE) has been used to 
investigate the role of different immune population in CNS autoimmunity. EAE is a model of 
autoimmunity driven by myelin-specific CD4+ T cells, and several related models have been 
developed using mice, rats, and non-human primates38.  In C57Bl/6 mice, there are two disease 
induction methods.  Disease may be induced by active immunization with a peptide of myelin 
oligodendrocyte glycoprotein (MOG35-55) in combination with Complete Freund’s Adjuvant and 
two doses of pertussis toxin.  Mice generate a CD4+ T cell response toward the myelin peptide 
which leads to activation of the T cells, immune infiltrating into the CNS, and the initiation of 
inflammation and damage.  Histological examination reveals demyelinating lesions and dense 
infiltrates in the brain and spinal cord39.  The clinical outcome is an ascending paralysis 
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approximately two weeks after immunization, and the level of disability is scored on a scale 0-5.  
It begins with a limp tail and hind-limb weakness that progresses to full hind-limb paralysis with 
occasional fore-limb involvement.  The mice are permanently disabled and do not recover, so 
this is described as a chronic model of CNS autoimmunity (Figure 1.2A).  Disease may also be 
induced by adoptive transfer of myelin-specific T cells.  In this method, donor mice are 
immunized with myelin peptide and adjuvant.  After two weeks, immune cells are collected from 
the lymph nodes which drain the immunization sites and cultured with myelin peptide and 
polarizing factors for 4 days.  At the end of culture, CD4+ T cells are purified and transferred 
intraperitoneally into a naïve recipient.  Mice develop paralysis approximately 1 week after cell 
transfer but follow a similar chronic clinical course40 (Figure 1.2B).   
 
 
Figure 1.2 - Clinical courses of EAE models. 
 
While these models in C57Bl/6 mice recapitulate the demyelinating lesions of MS, they 
lead to chronic disability and do not have the relapsing-remitting course observed in the majority 
of MS patients.  To model the course of RRMS, a different strain can be used41.  SJL mice 
immunized with a peptide of the myelin proteolipid protein (PLP139-151) develop hind limb 
paralysis approximately 2 weeks after immunization but regain function by 3 weeks post 
immunization (remission).  At four weeks post immunization, many of the mice will begin to 
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develop paralysis for the second time (relapse).  In this way, the SJL mice display a relapsing 
remitting course (Figure 1.2C).  The inflammatory cell infiltrate in the CNS correlates with the 
degree of severity, expanding during relapse and contracting during remission42.   
 
Myeloid cells in MS and EAE 
Our laboratory and others have demonstrated that myeloid cells are critical for early EAE 
pathogenesis.  The numbers of infiltrating monocytes in the CNS correlate with disease 
severity43.  Depleting monocytes or blocking their recruitment abrogates disease44–47 whereas 
enhancing Ly6C+ monocytes in the blood exacerbates disease48.  There are several effector 
functions of myeloid cells that may be pathogenic in EAE.  Myeloid cells may re-activate 
myelin-specific CD4+ T cells49,50, secrete pro-inflammatory cytokines such as IL-6, IL-12, and 
IL-2329,51,52, and release toxic factors such as TNFα and nitric oxide to directly inflict damage53.  
Monocyte-derived macrophages are in close proximity to demyelinating axons and contain 
myelin debris, suggesting an active role in demyelination54.  Similar observations have been 
made in active MS lesions including oxidative damage55 and phagocytosed myelin debris56. 
The pathogenic role for myeloid cells is clear, but there is increasing evidence that 
myeloid cells may also be protective in EAE.  Peripheral injection of macrophages stimulated 
with immune complexes57 or with IL-1058 can suppress EAE.  Similarly, intracerebroventricular 
transfer of microglia stimulated with IL-4 can reduce the severity of EAE59.  Monocytes 
incubated with glatiramer acetate, one of the approved therapies for MS, can also reduce the 
severity of EAE60.  How are the myeloid cells exerting this positive influence?  These 
alternatively-activated myeloid cells may produce higher levels of anti-inflammatory cytokines 
such as IL-10 and TGFβ1 or reduced levels of pro-inflammatory factors such as IL-1257,60.  The 
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cells may produce trophic factors to promote oligodendrocyte maturation61 or axon growth62.  
The phagocytic function of macrophages may itself have protective role as blockade of TREM2, 
a key phagocytic receptor, exacerbates EAE63.  These studies demonstrate the dual role myeloid 
cells may have in neuroinflammation, and more investigation is necessary to understand the 
functional and phenotypic heterogeneity of myeloid cells in CNS autoimmunity. 
 
Phenotype vs. lineage 
At this point, an important distinction must be made between cell phenotypes and 
developmental lineages.  Phenotypes are transcriptional programs induced by stimuli in the 
setting of inflammation, such as classically or alternatively activated.  The same cell may be 
polarized to distinct phenotypes by different signals, and thus there is the potential for plasticity 
between these phenotypes.  For example, a macrophage may be secreting a pro-inflammatory 
cytokine at one moment and an anti-inflammatory cytokine the next but is always a macrophage.  
Developmental lineages are cell fates that diverge at the point of differentiation from a 
progenitor in a hematopoietic organ.  B cells and T cells, for example, are derived from the same 
precursor but differentiate in the bone marrow to distinct lineages.  It is easy to appreciate this 
difference because we have identified markers unique to these lineages.  However, this is not 
always the case. 
 
Myeloid cell lineages 
A recent study set out to determine the origin of myeloid cell subsets in the naïve CNS.  
Using transgenic mice to fate map cell lineages, Goldmann et al64 compared the source of 
microglia, perivascular macrophages, choroid plexus macrophages, and meningeal macrophages.  
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These populations were defined as myeloid cells by expression of the marker Iba-1.  The 
nomenclature, however, is complicated as many of the cells are not derived from common 
myeloid precursors in the bone marrow.  Microglia are a tissue resident population that 
comprises the majority of myeloid cells in the naïve CNS.  Though microglia perform as 
mononuclear phagocytes like macrophages and express many of the same markers, microglia are 
not derived from the bone marrow.  Instead, microglia are derived from the yolk sac during 
embryogenesis65,66 and are locally sustained in the adult67.   Microglia are located within the 
parenchyma of the tissue, but other macrophages have been identified at interfaces with the 
periphery such as the blood vessels, meninges, and choroid plexus.  These border macrophages 
can be distinguished from microglia by higher expression of the cell markers CD45 and CD11b.  
It was thought that the border macrophages were classical myeloid cells derived from the bone 
marrow, but Goldmann et al64 demonstrated their origin is mixed.  Some of these cells persist 
from embryogenesis like microglia but others are replenished from the bone marrow.  The 
functional implications of this heterogeneity are unknown.  This study provides an example of 
the diversity of lineages in the naïve CNS.  In the setting of neuroinflammation, many of these 
resident populations are indistinguishable from the infiltrate using standard markers, and analysis 
is further complicated.  If consideration is not given to identification of myeloid cell lineages, 
analysis of phenotypes may be confounded by the heterogeneity of the population.   
The distinction between cell lineages is especially difficult but not less important in a 
subset of myeloid cells called dendritic cells (DC).  DCs were initially described by their large 
nuclei and extended dendrites68.  This umbrella classification includes cells diverse in both 
phenotype and lineage.  With the discovery of cell surface markers, DCs were further refined in 
mice to be cells with high expression of MHC-II and CD11c.  This classification remains 
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heterogeneous, and many attempts have been made to split this group into meaningful subsets.  
A primary split can be made between cells of the monocyte-derived versus conventional DC 
lineages69 (Figure 1.3).  Monocyte-derived DC (moDC) differentiate from monocytes such that 
the cells leave the bone marrow as monocytes, travel to the site of inflammation as monocytes, 
and differentiate in tissues in response to inflammatory stimuli such as GM-CSF70,71.  In contrast, 
conventional dendritic cells (cDC) are derived from a pre-DC population in the bone marrow and 
populate tissues and lymphoid organs during homeostasis72.  cDCs in tissues are continuously 
replenished by progenitors from the bone marrow in a Flt3-dependent manner73 and may expand 
in the setting of inflammation74.  moDC and cDC share many of the same surface markers, so it 
has been difficult to distinguish these lineages.  As a result, it is unclear whether these subsets 
have distinct or overlapping functional roles.   
 
Figure 1.3 – Dendritic cell developmental lineages.   
CMP, common myeloid precursor; MDP, macrophage DC progenitor; CDP, common DC 
progenitor; Mono, monocyte; Macro, macrophage; moDC, monocyte-derived DC; pre-DC, 




Markers to identify DC lineages 
CD64 and CD88 have recently been identified as markers of the monocyte lineage75–78.  
These markers are not specific to dendritic cells but do specifically identify monocyte-derived 
cells within the CD11c+MHCII+ population.  Some reports question whether CD64 effectively 
discriminates moDC and cDC in all tissues79, but the specificity of CD88 has confirmed in the 
lung, spleen, kidney, liver, and small intestine78.  CD88 (C5ar1) is a complement receptor 
expressed on neutrophils, eosinophils, monocytes, and even some non-hematopoietic cells such 
as neurons and astrocytes80.  Conversely, CD26 (dipeptidyl peptidase 4), an enzyme involved in 
peptide hydrolysis, has been identified as a marker with expression on cDC but not moDC.  In 
addition to cDC, CD26 is expressed by activated T and B cells81, plasmacytoid DCs, and many 
non-hematopoietic cells including stromal cell of the CNS meninges82.  Though CD88 and CD26 
are widely expressed, the combination of these markers permits the distinction of the moDC and 
cDC lineages within the DC compartment and is therefore a vital tool in discriminating 
functional roles for moDC and cDC in inflammation. 
The transcription factor Zbtb46 (BTBD4) has also been identified as a specific marker of 
cDC in both mice and humans83,84.  Its expression is more specific than CD26, but there is still 
additional expression in definitive erythroid precursors and endothelial cells84.  To evaluate the 
function of cDCs, Meredith et al generated Zbtb46-DTR mice to allow specific depletion of 
Zbtb46-expressing cells by administration of diphtheria toxin83.  A single dose, however, proved 
lethal.  To focus on the role of Zbtb46 in hematopoietic cells, Zbtb46-DTR bone marrow was 
used to generate chimeras.  Using this system, Meredith et al demonstrated that Zbtb46-DTR 
specifically depletes cDC in multiple organs without depleting moDCs.  Furthermore, depletion 
of Zbtbt46-expressing cells abrogated both CD4+ and CD8+ T cell responses to immunization, 
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pointing to a critical role for cDC in antigen presentation.  This transgenic mouse provides a 
powerful tool to specifically target cDC and evaluate their role in homeostasis and disease. 
Several groups have used these tools to investigate the roles of moDC and cDC in other 
disease models.  Both cDC and moDC are present in the lung, and cDC displayed an enhanced 
capacity to activate T cells compared with moDC78.  Both cDC and moDC are also present in the 
heart following myocardial infarction, but cDC are superior at activating autoreactive CD4+ T 
cells ex vivo85.  Depleting cDC with the Zbtb46-DTR mice impairs CD4+ and CD8+ T cell 
responses to immunization with functional implications on tumor responses83.  Specific depletion 
of MHCII on Zbtb46-expressing cells also abrogated T cell responses to immunization and 
impaired antimicrobial adaptive immune responses in the gut86.  These studies begin to 
demonstrate the distinct roles of moDC and cDC in inflammatory processes in diverse tissues, 
but many questions remain.  Future study is necessary to evaluate the presence of these subsets 
in the CNS and to determine the functional role of these subsets in MS and EAE.      
 
Specific Aims 
Myeloid cells are a prominent component of CNS inflammatory lesions that accumulate 
in individuals with MS and in laboratory animals with EAE.  There is increasing evidence that 
these myeloid cells are heterogenous in both phenotype and developmental lineage, but the 
implications of this heterogeneity are unclear.  Myeloid cells may by pathogenic by promoting 
and sustaining inflammation within the CNS or have anti-inflammatory properties and play a 
role in the resolution of inflammation and initiation of repair.  Current therapies for MS do not 
discriminate between myeloid cell subsets.  Investigating the diversity of myeloid cell 
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phenotypes may reveal novel methods to specifically target pathogenic immune cells while 
preserving protective subsets and promoting recovery during autoimmune demyelinating disease. 
In this dissertation, we undertake the investigation of myeloid cells in CNS autoimmunity 
in two parts: 
o Aim 1: Chapter 2: Investigate myeloid cell phenotypes and function in MS and EAE.  We 
use iNOS and Arg1 as markers of myeloid cell phenotypes and characterize the evolution of 
these phenotypes on the single cell level in disease. 
o Aim 2: Chapter 3: Determine the roles of monocyte-derived versus conventional dendritic 
cells in EAE.  We identify multiple DC lineages in the CNS and characterize their distinct 
functions and contributions to disease. 
These studies provide critical insights into the immunopathology of CNS autoimmunity and can 




Chapter 2 - Myeloid cell plasticity in the evolution of central nervous system autoimmunity 
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Abstract 
Objective:  Myeloid cells, including macrophages and dendritic cells, are a prominent 
component of central nervous system (CNS) infiltrates during multiple sclerosis (MS) and the 
animal model experimental autoimmune encephalomyelitis (EAE).  Although myeloid cells are 
generally thought to be pro-inflammatory, alternatively-polarized subsets can serve non-
inflammatory and/or reparative functions.  Here we investigate the heterogeneity and biological 
properties of myeloid cells during central nervous system autoimmunity.  Methods: Myeloid cell 
phenotypes in chronic active MS lesions were analyzed by immunohistochemistry.  In addition, 
immune cells were isolated from the CNS during exacerbations and remissions of EAE and 
characterized by flow cytometric, genetic and functional assays.  Results:  Myeloid cells 
expressing iNOS, indicative of a pro-inflammatory phenotype, were detected in the actively 
demyelinating rim of chronic active MS lesions, whereas macrophages expressing mannose 
receptor (CD206), a marker of alternatively-polarized human myeloid cells, were enriched in the 
quiescent lesion core.  During EAE, CNS-infiltrating myeloid cells, as well as microglia, shifted 
from expression of pro- to non-inflammatory markers immediately prior to clinical remissions.  
Murine CNS myeloid cells expressing the alternative lineage marker arginase-1 (Arg1) were 
partially derived from iNOS+ precursors and were deficient in activating encephalitogenic T cells 
16 
 
compared with their Arg1- counterparts.  Interpretation:  These observations demonstrate the 
heterogeneity of CNS myeloid cells, their evolution during the course of autoimmune 
demyelinating disease, and their plasticity on the single cell level.  Future therapeutic strategies 
for disease modification in individuals with MS may be focused on accelerating the transition of 
CNS myeloid cells from a pro- to a non-inflammatory phenotype. 
 
Introduction 
Myeloid cells, including macrophages (MΦ) and dendritic cells (DC), are a major 
component of white matter lesions in multiple sclerosis (MS) and the animal model experimental 
autoimmune encephalomyelitis (EAE)87,88.  Our laboratory and others have established a critical 
role of myeloid cells in early EAE pathogenesis43,45,48,89.  Myeloid cells may serve as antigen 
presenting cells for re-activation of myelin-specific CD4+ T cells49,50, secrete cytokines such as 
IL-6, IL-1β, and TNFα29, and directly inflict damage through release of toxic factors such as 
reactive oxygen species generated by inducible nitric oxide synthase (iNOS)90,91.  iNOS-
expressing myeloid cells are often described as classically-activated, and considered “pro-
inflammatory”, based on their similarity to bone marrow derived macrophages (BMDM) 
polarized with LPS or IFNγ in vitro28.  It is generally thought that classically-activated myeloid 
cells (CAMC) are predominant in active MS and EAE lesions where they act as pathogenic 
effector cells92–94.  Early studies of autopsied MS brains revealed iNOS-immunoreactive 
macrophages in active lesions93,95,96. The presence of iNOS+ myeloid cells generally correlated 
with zones of ongoing demyelination.  
However, there is growing evidence that myeloid cells that accumulate in the central 
nervous system (CNS) are heterogeneous and likely encompass a spectrum of lineages with 
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diverse, and even opposing, properties56,97,98.  In contrast to iNOS, the enzyme arginase-1 (Arg1) 
and the mannose receptor CD206 have been identified as markers of myeloid cells with 
“immunosuppressive” or “pro-regenerative” properties.  Arg1/CD206-expressing myeloid cells 
play a critical role in wound healing99.  They are frequently classified as alternatively-activated 
based on their similarity to BMDM generated in vitro by polarization with IL-4 or IL-13 via a 
STAT6-dependent pathway26,28.  Alternatively-activated myeloid cells (AAMC) may regulate the 
inflammatory environment by secreting IL-10 and/or TGFβ129, while promoting tissue 
regeneration by clearing debris100,101 and secreting growth factors61.  Foamy (lipid-laden) 
macrophages, perivascular macrophages, and microglia expressing human AAMC markers, such 
as CD206 and CD163, have been discovered in acute and chronic active MS lesions56,61,88,102.  
Primary human macrophages acquire a foamy morphology and produce immunosuppressive 
factors following ingestion of myelin in vitro56.   
We questioned whether CNS myeloid cells evolve during disease progression and shift 
from a pro-inflammatory phenotype at onset to a non-inflammatory or immunosuppressive state 
in anticipation of clinical remission/stabilization. Consistent with this hypothesis, CNS-
infiltrating DC were found to upregulate the AAMC-associated genes Arg1, Chi3l3 and Ms4a8a 
at the peak of EAE, shortly prior to remission103.  In fact, Arg1 is the most-significantly up-
regulated gene in the CNS at peak EAE104.  Adoptive transfer of AAMC- polarized macrophages 
or microglia can ameliorate EAE58,105, and the therapeutic effects of estrogen, glatiramer acetate 
and other agents in EAE were found to correlate with the expansion of AAMC in the periphery 
and/or CNS60,106–108.  Less is known about endogenous AAMC that spontaneously accumulate in 
the CNS during the course of EAE or MS.  In the current paper, we compare the spatial 
distribution of AAMC in actively demyelinating and quiescent regions of MS lesions.  In 
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addition, we examine the origin, kinetics and biological properties of CNS myeloid subsets from 
the preclinical stage of EAE through peak and remission. 
 
Methods 
Mice.  C57Bl/6 and B6.Ly5.1 mice were from Charles River Laboratories.  Arg1-eYFP109, Rosa-
LSL-eYFP, 2D2 TCR transgenic, and STAT6-/- mice were from the Jackson Laboratory.  iNOS-
TdTomato-Cre110 mice were from the European Mouse Mutant Archive.  SJL mice were from 
Harlan Laboratory.  Both male and female mice, age 6-12 weeks, were used in experiments.  All 
mice were bred and maintained under specific pathogen-free conditions at the University of 
Michigan, and all animal experiments were performed in accordance with an IACUC-approved 
protocol at the University of Michigan. 
 
Induction and assessment of EAE.  For active immunization, C57Bl/6 mice were subcutaneously 
immunized over the flanks with 100 µg MOG35-55 (Biosythesis) in complete Freund’s adjuvant 
(Difco).  Mice were injected intraperitoneally with 300 ng pertussis toxin (List Biological) on 
days 0 and 2.  For adoptive transfer, mice were immunized as described, without pertussis toxin, 
and the draining lymph nodes (inguinal, brachial, and axillary) were collected at 10-14 days post-
immunization.  Lymph node cells were cultured for 96 hours in the presence of 50 ug/mL 
MOG35-55, 8 ng/ml IL-23 (R&D Systems), 10 ng/ml IL-1α (Peprotech), and 10 µg/mL anti-IFNγ 
(Clone XMG1.2, BioXcell).  At the end of culture, CD4+ T cells were purified with CD4 positive 
selection magnetic beads (Miltenyi), and 3-5x106 CD4+ T cells were transferred intraperitoneally 
into naïve recipients.  For induction of relapsing-remitting EAE, SJL mice were subcutaneously 
immunized over the flanks with 100 µg PLP139-151 (Biosynthesis) in complete Freund’s adjuvant 
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(Difco) without pertussis toxin.  EAE was assessed by a clinical score of disability: 1, limp tail; 
2, hind-limb weakness; 3, partial hind-limb paralysis; 4, complete hind-limb paralysis; and 5, 
moribund state. 
 
Mixed bone marrow chimeras.  B6.Ly5.1 (CD45.1+) congenic hosts were lethally irradiated with 
1300 Rad split into two doses and reconstituted by tail vein injection of 4x106 bone marrow 
cells.  Cells were a 50:50 mix of B6.Ly5.1 WT (CD45.1+) and STAT6-/- (CD45.2+) bone 
marrow.  Mice were allowed to reconstitute for 6 weeks prior to use.  Expression of CD45.1 or 
CD45.2 was used to distinguish WT and STAT6-/- cells from the same animal for analysis.   
 
Cell isolation.  Mice were anesthetized with isoflurane.  Mice were perfused with PBS through 
the left ventricle.  Draining lymph nodes and spleens were isolated, and a single-cell suspension 
was generated by passing cells through a 70-µm mesh filter.  For collection of CNS mononuclear 
cells, brains were dissected from the skull, and spinal cords were flushed from the spinal column 
with PBS.  Tissues were homogenized with an 18G needle and syringe in a solution containing 1 
mg/ml collagenase A (Roche) and 1 mg/ml DNase 1 (Sigma-Aldrich) in HBSS and incubated at 
37°C for 20 minutes.  Mononuclear cells were separated from myelin with a 27% Percoll 
gradient (GE Healthcare).   
 
Flow cytometry.  Mononuclear cells were labelled with fixable viability dye (eFluor506 or 
eFluor780, eBioscience), blocked with anti-CD16/32 (Clone 2.4G2, hybridoma), and stained 
with fluorescent antibodies.  For intracellular staining, cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.5% saponin, and stained with fluorescent antibodies.  
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Antibodies for CD62L (Clone MEL-14) and Ly6G (Clone 1A8) were obtained from BD 
Biosciences.  The following antibodies were obtained from eBioscience: CD45 (Clone 30-F11), 
CD11b (Clone M1/70), CD11c (Clone N418), NOS2 (Clone CXNFT), CD44 (Clone IM7), CD4 
(Clones RM4-5, GK1.5), MHC-II (Clone AF6-120.1), CD40 (Clone HM40-3), CD80 (Clone 16-
10A1), CD86 (Clone GL1).  Antibodies were conjugated to FITC, PE, PeCy7, APC, APC-Cy7, 
PerCP-Cy5.5, PerCP-eFluor710, PE/Dazzle 594, eFluor450, or PE-eFluor610.  Arginase was 
stained with FITC-conjugated antibody (IC5868F, R&D Systems) or with unconjugated antibody 
(AF5858, R&D Systems) and an AlexaFluor 647-conjugated donkey anti-sheep secondary 
(ThermoFisher).  Data was acquired using a FACSCanto II flow cytometer or FACSAria III flow 
sorter (BD Biosciences) and analyzed with FlowJo software (Treestar).  Cells were sorted with a 
FACSAria III flow sorter (BD Biosciences). 
 
Quantitative PCR.  Sorted cells were resuspended in RLT buffer, and RNA was isolated with the 
RNeasy Mini Kit (Qiagen).  cDNA was generated by reverse transcription with the High 
Capacity cDNA Reverse Transcription Kit (Life Technologies).  qPCR was performed on an iQ 
Thermocycler (Bio-Rad) using the iQ SYBR Green Supermix.  Relative gene expression was 
determined with the ΔCT method with normalization to Actb. 
 
Ex vivo cultures.  For purification of naïve CD4+ T cells, lymph nodes and spleen were collected 
from naïve 2D2 TCR transgenic mice, and CD4+ T cells were enriched by positive selection with 
magnetic beads (Miltenyi).  To further isolate naïve T cells, cells were sorted for live 
CD4+CD44-CD62L+ T cells.  For purification of memory T cells, mononuclear cells from the 
CNS were flow sorted for live CD45+CD11b-CD3+CD4+MHC-II- T cells.  T cells were labeled 
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with CFSE according the manufacturer’s instructions (ThermoFisher).  Myeloid cell populations 
were sorted with markers as indicated in the text.  Myeloid cells and T cells were co-cultured in 
complete RPMI for 96 hours at a ratio of 1:20 (typically 5,000 myeloid cells with 95,000 T cells) 
in the presence or absence of myelin antigen (MOG35-55 peptide [Biosynthesis]).   
 
Multiplex immunoassays.  Cell culture supernatants were analyzed with the Milliplex Mouse 
Th17 Cytokine Panel (EMD Millipore) using the Bio-Plex 200 System (Bio-Rad).  Values below 
the reported level of detection of the assay (minDC) were assigned a value of 0.5*minDC for 
statistical analysis and represented on graphs as not detectable (n.d.). 
 
Immunohistochemistry on MS brain tissue.  Human CNS tissue was obtained at autopsy 
according to an Institutional Review Board-approved protocol at Yale University. CNS tissue 
was obtained from 4 subjects with MS and a total of 5 chronic active white matter lesions were 
examined. Lesions were identified as “chronic active” according to the classification proposed 
by Bruce Trapp111.  Specifically, lesions were characterized by ongoing demyelination at the 
lesion rim, with dense infiltration of CD68-positive myeloid cells that contained myelin 
degradation products. The lesion center was demyelinated but still contained lipid-positive 
myeloid cells. Post mortem intervals were between 5.5 and 24 hrs. Brain tissue was fixed with 
10% formalin for 2 to 4 weeks and embedded in paraffin.  Formalin-fixed, paraffin-embedded 
(FFPE) sections were cut, quenched with hydrogen peroxide and blocked with normal serum, 
incubated with primary antibodies overnight and finally processed with the appropriate 
biotinylated secondary antibody and avidin/biotin staining kit with diaminobenzidene as 
chromogen (Vector ABC Elite Kit and DAB Kit, Vector Laboratories), and counterstained with 
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haematoxylin. The following antibodies were used in this study: MBP (Rabbit polyclonal, Dako 
A0623), CD68 (Mouse monoclonal, Dako M0876), iNOS (Rabbit polyclonal, Novus NB 120-
15203), CD206 (Mouse polyclonal, Abcam ab117644), and Iba-1 (Goat polyclonal, Abcam 
ab5076).  Adequate controls using isotype control antibodies were performed with each primary 
antibody. Brightfield images were acquired with a Leica DM5000 B microscope using a Leica 
colour camera DFC310 Fx and the Leica Application Suite (version 4.2.0) imaging software. For 
fluorescence images, sections were incubated with fluorescent-labelled secondary antibodies and 
subsequently treated with 0.7% Sudan Black in ethanol and CuSO4 to quench auto- 
fluorescence. Sections were counterstained with DAPI and mounted with VectaShield mounting 
medium (VectaShield Kit, Vector Laboratories). Images were acquired with an UltraVIEW VoX 
(Perkin Elmer) spinning disc confocal Nikon Ti-E Eclipse microscope. Image acquisition, 
visualization and quantification were performed using the Volocity 6.3 soft- ware (Improvision). 
Images were processed with the ImageJ software (Schneider et al., 2012). For 3D Surface plots, 
colors were split into red, green and blue, and only the red color images were processed further. 
Background was removed by setting an appropriate threshold and the resulting image was 
processed with the “Interactive Surface Plot v2.4” ImageJ plug-in. 
 
Statistics.  Statistical analysis was performed using paired or un-paired, 2-tailed Student’s t test, 
as indicated in the legends. 
 
Results 
Macrophage polarization shifts from the core to the rim of MS lesions 
In order to characterize the polarization state of CD68+ macrophage in chronic active MS 
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lesions, we immunolabelled brain tissue sections from 4 patients (Table 2.1) with antibodies 
against iNOS and CD206, the standard markers of classically and alternatively activated human 
myeloid cells, respectively88,93,112,113.  MS lesions tend to grow centrifugally over time, with 
inflammatory activity gradually moving outward. Chronic active lesions have a relatively 
quiescent and hypocellular lesion center, due to waning of the earlier inflammatory response, 
surrounded by a rim of macrophages with early myelin degradation products, signifying ongoing 
demyelination111.  We found that a high percentage of CD68+ macrophages at the lesion rim 
were iNOS+, while relatively few macrophages expressed CD206 (Figure 2.1A-D). Conversely, 
the ratio of CD206+ cells was higher than iNOS+ cells among those macrophages in the center of 
the lesion.  We detected iNOS/CD206 double positive macrophages in all 5 MS lesions, which 
were most numerous in the lesion center (Figure 2.1E).  Consistent with our results, Vogel and 
colleagues discovered foamy macrophages and activated microglia in a panel of active MS 





Figure 2.1 - CD206+ and iNOS+ macrophages are distributed from the center to the rim of 
active MS lesions.  
(A) Chronic active MS lesion immunolabeled for myelin basic protein (MBP) and CD68. (B) Cross 
sections of the same lesion, extending from the lesion center to the lesion rim, immunolabeled for CD206 
and iNOS. (C) Quantification of iNOS+ and CD206+ cells at the lesion center and lesion rim. The number 
of cells is expressed as a percentage of CD68+ cells. N=5 lesions quantified.  *P<0.05, **P<0.01 by 
paired, 2-tailed Student’s t test.  (D) Surface plots of sections in B with the number of stained cells 
expressed as height, processed with the “Interactive Surface Plot v2.4” ImageJ plug-in. (E) 
Representative immunofluorescent labeling for CD206 (white), iNOS (magenta), and Iba1 (yellow).  Scale 
bars indicate 150 µM (A); 100 µM (B) and 10 µM (E). 
 
Table 2.1 – Clinical data of MS patients included in this study. 
Case Age Gender Disease Course Disease duration 
Post-mortem 
Interval 
1 42 Male RRMS 20 yrs 5.5 hrs 
2 37 Male RRMS 15 yrs 24 hrs 
3 50 Female RRMS 10 yrs 6 hrs 




Arg1 is expressed by a subset of CNS-infiltrating myeloid cells at peak EAE 
Next, we investigated the phenotypes of CNS myeloid cells during the course of EAE.  
We found that the myeloid cells that accumulate in the CNS do not reliably express CD206, but a 
subset of splenic myeloid cells consistently expressed CD206 at high levels (data not shown).  
Since Arg1 is commonly used to identify murine AAMC28, we measured expression of iNOS 
and Arg1 in inflammatory cells isolated from the spinal cord at serial time points following 
active immunization with myelin peptide.  We detected iNOS, but not Arg1, in mononuclear 
cells isolated from the spinal cord at clinical onset (Figure 2.2A).  In contrast, at peak disease we 
detected Arg1, but not iNOS, in the CNS myeloid cells.  Arg1 was expressed by CD45hiCD11b+ 
infiltrating myeloid cells and CD45intCD11bint resident microglia, but not by CD45+CD11b- 
lymphoid cells or CD45- nonhematopoietic cells (Figure 2.2B).  The CD45hiCD11b+ myeloid 
subset was further divided into Ly6G+ neutrophils, CD11c- monocytes/ macrophages (MΦ), and 
CD11c+ dendritic cells (DC).  Arg1 was expressed by a significant percent of the infiltrating MΦ 
and DC, but not by neutrophils.  At clinical onset, expression of iNOS followed a similar pattern 
both in spinal cord and brain mononuclear cells (data not shown).  Arg1+ and iNOS+ myeloid 
cells were restricted to the CNS as no Arg1+ or iNOS+ cells were detected in the spleen, draining 





Figure 2.2 - Arg1 expression defines a distinct myeloid cell population that accumulates in 
the CNS during later stages of EAE.  
(A, B) EAE was induced in mice by active immunization with myelin peptide.  Inflammatory cells were isolated 
from the CNS at the onset or peak of clinical disability.  Representative intracellular staining of Arg1 and iNOS in 
CNS immune cells from WT mice gating on (A) all viable cells at onset or peak or (B) cell subsets at peak disease.  
(C) Arg1+ and Arg1- myeloid cells were flow sorted from the CNS of Arg1-eYFP reporter mice.  M1 and M2 related 
transcripts were measured by qRT-PCR.  Data are represented as the ratio of gene expression in Arg1+ cells over 
Arg1- cells. (D)  Inflammatory cells were isolated from the CNS of STAT6-/-:WTWT mixed bone marrow 
chimeric mice at the peak of EAE.  Representative flow and quantification of intracellular staining of Arg1 and 
iNOS in WT or STAT6-/- cells, gated on the CD45hiCD11b+Ly6G- population. Percentages are Arg1+ cells among 
WT or STAT6-/- CNS myeloid cells isolated from individual chimeric mice. Connected dots indicate cells derived 
from the same mouse. *P<0.05, **P<0.01, ***P<0.001 and n.s. = P>0.05, by paired, 2-tailed Student’s t test.  Data 
are representative of at least 2 experiments.  N=3-5 mice per group.  All values are mean ± SEM. 
  
We sorted Arg1+ and Arg1- MΦ (CD45hiCD11b+Ly6G-CD11c-) or DC 
(CD45hiCD11b+Ly6G-CD11c+) from the CNS of Arg1-eYFP reporter mice109 during peak stage 
EAE, and we measured the expression of candidate genes by quantitative RT-PCR.  Genes 
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associated with in vitro generated AAMC, including Ym1 and Mrc1, were enriched in Arg1+ 
CNS DC and MΦ, compared with their Arg1- counterparts, while CAMC-related genes (iNOS, 
IL-1β, IL-6) were unchanged or reduced (Figure 2.2C).  The genetic profiles of Arg1+ and Arg1- 
CNS myeloid cells did not precisely mirror those of in vitro generated AAMC and CAMC, 
respectively.  For example, mRNA encoding the AAMC-associated cytokines IL-10 and TGFβ1 
were expressed at similar levels Arg1- and Arg1+ cells, and the CAMC-associated cytokine 
TNFα was expressed at relatively high levels in the CD11c-Arg1+ cohort.  Reminiscent of these 
results, an Arg1+ CNS myeloid subset with a mixed gene profile was recently described in 
traumatic brain injury114, which may signify a distinct myeloid cell phenotype induced within the 
CNS microenvironment.   
 
Arg1+ myeloid cells accumulate in the CNS independent of STAT6 
STAT6 has been identified as a critical regulator of Arg1 expression in BMDMs in 
response to IL-4 and IL-13 in vitro115.  To determine whether STAT6 is also critical for the 
accumulation of Arg1+ CNS myeloid cells during EAE, we constructed mixed bone marrow 
chimeric mice by reconstituting lethally irradiated WT mice with a combination of STAT6-/- and 
WT bone marrow cells.  Brain and spinal cord mononuclear cells were isolated from individual 
chimeric mice at peak EAE for flow cytometric analysis.  The frequency of Arg1+ cells was 
modestly reduced among STAT6-/-, compared with WT, myeloid cells isolated from the same 
CNS tissue (Figure 2.2D).  Nonetheless, the accumulation of Arg1+ CNS myeloid cells was 




Myeloid cells shift from iNOS to Arg1 expression during the evolution of adoptively 
transferred and relapsing remitting EAE 
Active immunization involves the administration of CFA and pertussis toxin which could 
directly modulate innate immune cells.  In order to determine how iNOS and Arg1 expression 
evolves in CNS myeloid cells during EAE in the absence of adjuvant, we utilized an adoptive 
transfer model.  Naïve C57BL/6 mice were injected with myelin-primed syngeneic Th17 cells, 
and CNS mononuclear cells were isolated at serial time points for analysis by flow cytometry.  
Similar to our observations in the active immunization model, iNOS+Arg1- cells were prominent 
during the preclinical stage and at clinical onset, while iNOS-Arg1+ cells were prominent during 
peak and late disease (Figure 2.3A).  A population of iNOS+Arg1+ CNS myeloid cells also 
emerged at clinical onset but had contracted by peak EAE.  This dynamic shift in the expression 
of iNOS and Arg1 occurred in CNS-infiltrating MΦ and DC, as well as in CD45intCD11bint 




Figure 2.3 - Myeloid cells shift from iNOS to Arg1 expression in adoptive transfer and 
relapsing models of EAE. 
(A, B) EAE was induced by adoptive transfer of WT myelin-primed Th17 cells into naïve syngeneic hosts.  CNS 
inflammatory cells were isolated at serial time points and analyzed by flow cytometry.  (A) Representative 
intracellular staining of Arg1 and iNOS, gating on the CD45hiCD11b+Ly6G- population.  (B) Percentages of 
CD45hiCD11b+CD11c- MΦ, CD45hiCD11b+CD11c+ DC and CD45midCD11b+CD11c- microglia expressing iNOS 
and/or Arg1 in naïve mice (N) and in mice with EAE during the pre-clinical (PC), onset (O), peak (P), and late (L) 
stages of disease. (C-E) EAE was induced in SJL mice by active immunization with PLP139-151 peptide, and CNS 
inflammatory cells were collected at serial time points, including onset (O), peak of first episode (P), remission 
(Rem), and relapse (Rel). Cells were also collected from mice that experienced an initial exacerbation followed by 
remission but did not subsequently relapse (No Rel).  (C) Representative dot plots of intracellular iNOS and Arg1 
expression gating on the CD45hiCD11b+Ly6G- population. (D) Representative relapsing-remitting clinical course of 
SJL mice.  (E) Percentages of CD45hiCD11b+Ly6G- CNS myeloid cells expressing iNOS and/or Arg1 at serial time 




Next, we used a relapsing remitting model of EAE in SJL mice to determine whether 
myeloid cells undergo cyclical shifts in iNOS and Arg1 expression through multiple relapses.  
We observed that an iNOS+Arg1- subset accumulated immediately prior to the first exacerbation, 
contracted during peak disease, and rebounded at relapse (Figure 2.3C-E). In contrast, an iNOS-
Arg1+ subset expanded between the preclinical stage and peak EAE, waned during remission, 
and re-emerged at the peak of relapse.  Collectively, these results demonstrate that a shift in 
myeloid cell phenotype parallels clinical exacerbations and remissions/ plateaus and is consistent 
across multiple models of EAE. 
 
Individual myeloid cells convert from iNOS to Arg1 expression 
Khoury and colleagues described immunosuppressive Ly6Chi monocytes that expand in 
the periphery, accumulate in the CNS during EAE, and have the potential to differentiate into 
either iNOS+ or Arg1+ cells upon ex vivo culture with different polarizing factors98.  As shown in 
Figures 2.1 and 2.3, we detected myeloid cells in MS and EAE lesions that co-express AAMC 
and CAMC markers.  It is unclear if these cells represent a distinct, stable lineage or an 
intermediate stage during the transition between polarized subsets.  The experiments in Figures 3 
demonstrate the evolving characteristics of CNS myeloid cells on a population level; however, 
they do not address plasticity at the level of individual cells.  To this end, we permanently 
labelled iNOS+ cells and their descendants by crossing NOS2-TdTomato-Cre reporter mice110 
with Rosa26-LSL-eYFP reporter mice  to generate iNOS fate-mapping mice (iNOSFM).  Disease 
was induced in these mice by adoptive transfer of myelin-primed Th17 cells. A subset of 
myeloid cells isolated from the CNS of the fate mapping mice at peak EAE expressed eYFP, 
indicative of previous expression of iNOS (iNOSFM+) (Figure 2.4A-B).  At this point, iNOS 
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protein is no longer detectable.  Approximately 45% of the iNOSFM+ subset co-expressed Arg1 
(Figure 2.4C), demonstrating that individual CNS-infiltrating myeloid cells are capable of 
transitioning from expression of iNOS to expression of Arg1 during the course of disease. 
However, Arg1 expression is not absolutely dependent on prior expression of iNOS since ~15% 
of the iNOSFM- cells were also Arg1+.   Notably, a higher percentage of Arg1+ than Arg1- cells 
were derived from iNOSFM+ precursors (33% versus 9%).  These data demonstrate that Arg1-
expressing cells may be derived from iNOS-expressing cells or from iNOS-naïve cells. 
 
 
Figure 2.4 - Arg1-expressing CNS myeloid cells are derived, in part, from iNOS-expressing 
precursors. 
EAE was induced in mice by adoptive transfer of WT myelin-primed Th17 cells.  CNS inflammatory cells were 
analyzed by flow cytometry.  (A-C) Inflammatory cells were isolated from the spinal cords of iNOSFM mice at peak 
disease. (A-B) Representative dot plots showing iNOSFM and (A) Arg1 or (B) iNOS expression, gated on 
CD45hiCD11b+Ly6G- myeloid cells. (C) Percentages of CNS myeloid cell subpopulations defined according to 
iNOSFM and Arg1 expression.  Subpopulations were initially segregated based on expression of iNOSFM (left) or 
Arg1 (right).  Data are representative of at least 2 experiments.  N=3-5 mice per group. Mean values are shown.   
 
Arg1-expressing CNS myeloid cells are inefficient antigen presenting cells 
DCs have been identified as potent antigen presenting cells (APC) in the CNS during 
EAE49,116.  We sought to compare the APC function of Arg1+ versus Arg1- CNS DC by 
measuring the ability of each subset to promote myelin-specific T cell proliferation ex vivo.   
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Sorted CNS DC subsets were co-cultured with naïve 2D2 CD4+ T cells, which bear a transgenic 
T cell receptor specific for myelin oligodendrocyte glycoprotein peptide (MOG35-55), in the 
presence of myelin peptide.  Compared with their Arg1- counterparts, Arg1+ CNS DC were 
inefficient in promoting the proliferation of, or cytokine production by, myelin-specific T cells 
(Figure 2.5A-B).  Similar results were obtained when MOG1-125 protein was used as the recall 
antigen (data not shown).  The majority of CD4+ T cells within the CNS during EAE are 
CD44+CD62Llo effector cells.  In order to simulate antigen presentation within the CNS more 
closely, we next isolated CD4+ effector T cells from the spinal cords of mice at peak EAE and 
co-cultured them with Arg1+ or Arg1- CNS DC.  Similar to naïve 2D2 T cells, the CD4+ effector 
T cells proliferated and secreted cytokines at reduced levels in response to antigen presentation 
by Arg1+ versus Arg1- CNS DC (Figure 2.5C-D). The poor APC capacity of Arg1+ CNS DC did 
not appear to be due to low expression of MHC-II or co-stimulatory molecules (Figure 2.5E-F).  
Essentially all of the Arg1+ and Arg1- CNS DC expressed MHC-II, though Arg1+ cells expressed 
a slightly lower level than their Arg1- counterparts.  Arg1+ CNS DC expressed similar levels of 
the co-stimulatory marker CD40 and slightly higher levels of CD80 and CD86 compared with 
Arg1- CNS DC.  Arginase enzyme activity has been shown to suppress T cell proliferation in 
other experimental systems117,118; however, inhibition of arginase during co-cultures of T cells 




Figure 2.5 - Arg1+ cells are deficient at antigen presentation. 
EAE was induced in Arg1-eYFP reporter mice by active immunization with myelin peptide, and immune cells were 
isolated from the CNS at peak disease.  Arg1+ and Arg1- CD45hiCD11b+Ly6G-CD11c+ myeloid cells were flow 
sorted and co-cultured with MOG-reactive T cells in the presence of myelin peptide (MOG35-55).  (A-B)  CNS 
myeloid cell subsets were co-cultured with CD44-CD62L+ CD4+ T cells from naïve 2D2 TCR transgenic mice. (C, 
D) CNS myeloid subsets were co-cultured with CD4+ T cells isolated from the CNS of actively immunized WT 
mice at the peak of EAE. Graphs show (A, C) proliferation measured by CFSE dilution and (B, D) cytokine levels in 
culture supernatants, measured by multiplex bead assay.   (E, F) MHC-II and co-stimulatory marker expression were 
measured by flow cytometry on Arg1+ and Arg1- CD45hiCD11b+Ly6G-CD11c+ myeloid cells from the spinal cord at 
the peak of disease. (E) MHC-II expression quantified as both a percentage and by geometric MFI. (F) Co-
stimulatory marker expression quantified by geometric MFI.  *P<0.05, **P<0.01, and n.s. = P>0.05, by paired, 2-
tailed Student’s t test.  Data are representative of at least 2 experiments.  N=3-5 mice per group.   
 
We next investigated whether Arg1+ CNS myeloid cells are immunosuppressive or 
simply incompetent APCs.    Arg1+ CNS myeloid cells did not induce 2D2 T cells to upregulate 
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FoxP3 (data not shown) or to produce IL-10 (Figures 2.5B, D). Furthermore, the addition of 
Arg1+ CNS myeloid cells to co-cultures of Arg1- myeloid cells and 2D2 T cells did not impede 
antigen presentation by the Arg1- cells (data not shown).  Hence, we concluded that Arg1+ cells 
are intrinsically poor APC but do not actively block T cell activation by competent APC.     
 
Discussion 
Collectively, the data presented in our study demonstrate the heterogeneity and plasticity 
of myeloid cells within the CNS in MS and EAE.  We identified an Arg1+ CNS myeloid 
population during the peak and later stages of EAE which is deficient in the capacity to activate 
myelin-specific T cells. The appearance of Arg1+ myeloid cells in the CNS immediately prior to 
disease remission was consistent across multiple disease induction methods (active and adoptive) 
as well as across mouse strains (C57Bl/6 and SJL).  CNS Arg1+ DC were not 
immunosuppressive in the sense that they did not actively suppress T cell activation by their 
immunocompetent Arg1- counterparts.  Nevertheless, the poor antigen presenting ability of these 
myeloid cells may passively contribute to the resolution of inflammation, and hence to clinical 
remission, following peak disease.  The mechanism underlying ineffective antigen presentation 
by CNS Arg1+ myeloid cells remains to be elucidated.   We are currently interrogating the 
efficiency of myelin antigen loading on MHC-II molecules in CNS DC subsets.  It is also 
possible that the Arg1+ cells play an immunoregulatory or pro-regenerative role independent of T 
cell activation.  Although the Arg1+ cells do not produce IL-10 and express comparable levels of 
TGFβ1 to Arg1- cells, we are currently investigating whether they secrete other regulatory 
molecules.  CNS AAMC may play a role in ameliorating the clinical course by clearing 
debris100,101 and/or releasing trophic factors61. 
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Arg1+ CNS myeloid cells differ from in vitro polarized AAMC in that they differentiate 
in the absence of STAT6, express low levels of CD206 and high levels of MHC-II, and have a 
distinct genetic profile. The factors that drive their polarization in vivo are a subject of ongoing 
research.  Candidates include HIF1α and PPARγ, which have been shown to promote AAMC 
differentiation in other experimental systems119,120.  Alternatively, studies with primary human 
macrophages suggest that ingestion of myelin could trigger their development56.  Unexpectedly, 
we found that the Arg1+ CNS myeloid cells that accumulate in the CNS during EAE are derived, 
in part, from iNOS+ precursors.  Although plasticity of CAMC and AAMC has previously been 
demonstrated in other experimental systems on the population level, the current study is the first 
to our knowledge to directly demonstrate the transition of CNS myeloid cells from iNOS to Arg1 
expression in vivo on the single cell level.  Furthermore, during the transition from iNOS to Arg1 
expression, CNS myeloid cells entered an intermediary stage characterized by expression of both 
markers.  The demonstration by us and others88 that myeloid cells in MS lesions also co-express 
CAMC and AAMC markers raises the possibility that they undergo a dynamic transformation 
from a pro- to a non-inflammatory state.  Such a transformation is further suggested by the 
increasing gradient of iNOS versus CD206 expression in macrophages extending from the active 
rim to the quiescent center of chronic active MS lesions.    
Second generation disease modifying therapies (DMT) in MS suppress clinical 
exacerbations by depleting peripheral lymphocytes or blocking their trafficking to the CNS.  
While these reagents are highly effective in many individuals with relapsing-remitting MS, they 
are not cures, with up to 30% non-response rates.  Furthermore, DMT currently used in the clinic 
are generally ineffective in progressive forms of MS.   Myeloid cells and related factors have 
been under-utilized as candidate therapeutic targets in MS clinical trials.  This is particularly 
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relevant to secondary progressive MS, since numerous studies point to dysregulation of the 
innate arm of the immune system and, in particular, cells of the myeloid lineage as a distinctive 
feature of that stage of disease21–24.  The current findings suggest an opportunity for slowing, or 
even halting, progressive disability in patients with MS via the development of novel 
therapeutics that suppress pathogenic myeloid subsets in a targeted manner and/or promote their 





Chapter 3 – Conventional dendritic cells are critical for the initiation of experimental 
autoimmune encephalomyelitis 
 
**Portions of this chapter are being prepared for publication 
Giles DA, Duncker PC, Wilkinson N, Washnock-Schmid JM, Segal BM. Conventional dendritic 
cells are critical for the initiation of experimental autoimmune encephalomyelitis. 2017.  
 
Abstract 
Antigen presenting cells (APC) are required for the initiation of experimental 
autoimmune encephalomyelitis (EAE); however, the identity of the initiating APC is unknown.  
In this study, we investigate the role of dendritic cells (DC) as APC in EAE.  DC may arise from 
distinct lineages.  Monocyte-derived DC (moDC) differentiate from monocytes while 
conventional DC (cDC) differentiate from pre-DC precursors.  While the presence of moDC in 
EAE is known, it is not clear whether cDC are present in EAE or how cDC contribute to 
neuroinflammation.  Here, we identified cDC in the central nervous system (CNS) during EAE, 
and we demonstrated that CNS-derived cDC, but not moDC, were proficient at activating 
myelin-specific T cells.  We further characterized antigen-presenting cDC in the naïve CNS and 
showed that targeted depletion of these cDC was sufficient to reduce the incidence of adoptive 





Experimental autoimmune encephalomyelitis (EAE) is widely used as an animal model 
of multiple sclerosis (MS)38.  In this model, adoptive transfer of myelin-primed T cells is 
sufficient to promote neuroinflammation and an ascending paralysis.  T cells are activated in an 
antigen-specific manner by interaction with an antigen presenting cell (APC)121,122.  It remains 
unclear, however, what APC is required to initiate the neuroinflammatory process.   
APC are identified by expression of MHCII which allows presentation of antigen and 
recognition by CD4+ T cells.  There are several candidate APC which may be involved in MS 
and EAE.  Dendritic cells (DC), macrophages, and B cells are considered professional antigen 
presenting cells as these cells express both MHCII and co-stimulatory molecules requisite for T 
cell activation123.  Non-hematopoietic cells such as astrocytes have also been shown to express 
MHCII124,125, though it is unclear whether these cells possess the rest of the machinery necessary 
to be a competent APC126.  As a functional demonstration of this, Greter et al49 showed that 
MHCII expression on hematopoietic cells was required for adoptive transfer EAE while 
expression on non-hematopoietic cells was dispensable.  Furthermore, restricting MHCII 
expression to CD11c+ DCs was sufficient to permit disease induction.   
The CD11c+ DC population is heterogeneous and includes both monocyte-derived 
(moDC) and conventional (cDC) DC subsets127.  moDC are rare in homeostasis but differentiate 
from monocytes in the setting of inflammation.  In fact, monocytes, macrophages, and moDC 
may represent a continuum of activation as the cells differentiate and up-regulate MHCII and 
CD11c128,129.  In contrast, cDC are resident in both lymphoid and non-lymphoid tissues during 
homeostasis and expand in a Flt3-dependant manner130.  cDC are derived from a pre-DC 
precursor in the bone marrow and constitutively express MHC-II and CD11c131.  Plasmacytoid 
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DC (pDC) are a third population of DC derived from a similar pre-DC precursor; however, pDC 
express low levels of CD11c and MHCII, limiting their role as APC132.   
It has been difficult to distinguish moDC and cDC in vivo, and thus it is unclear how 
these distinct subsets contribute to an inflammatory response.  Recent work, however, has 
identified several markers which allow such discrimination.  CD88 (C5ar1), a complement 
receptor, and CD26 (DPP4), an enzyme involved in peptide hydrolysis, are expressed by moDC 
and cDC, respectively78.  These markers are not specific to DC but are effective in segregating 
the CD11c+ DC population.  The transcription factor Zbtb46 has also been identified as a marker 
of cDC in both mice and humans83,84.  
We and others have previously shown that CD11c+ cells accumulate in CNS during 
EAE89 and are derived from Ly6Chi monocytes48,133, suggesting the presence of moDC in 
disease.  It is not known whether cDC are also present.  A CD11c+MHCII+ DC population has 
been described in the naïve meninges in rodents134–136 and humans137.  Furthermore, recent 
studies have identified DC populations in the naïve meninges which expand in response to Flt3L, 
suggesting their identity as cDC138,139.  It is not clear whether or how these cells may contribute 
to neuroinflammation. 
Several studies have evaluated the role of DCs in EAE using CD11c-DTR mice, which 
allow depletion of CD11c+ cells by administration of diphtheria toxin (DT); however, the results 
have varied.  Depleting CD11c+ DC may ameliorate disease140,141, exacerbate disease142, or have 
no impact on the disease course44,143.  These studies differ in the DT dosing regimens and may 
thus differ in the efficiency of DC depletion in the CNS and periphery.  Furthermore, given the 
distinct types of DC, it is advantageous to separately target moDC and cDC, but CD11c-DTR 
does not distinguish between moDC and cDC.  Attempts have been made to target moDC with 
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CCR2-DTR mice44, but this is confounded by the simultaneous depletion of CCR2-expressing 
monocytes and macrophages.  To specifically target cDC, Zbtb46-DTR mice have been 
generated which allow focused study of the role of cDC in inflammation83.     
In the present study, we investigate the DC subsets present in the CNS during EAE.  We 
identify the presence of both moDC and cDC and demonstrate the CNS-derived cDC, but not 
moDC, are capable of activating myelin-specific CD4+ T cells.  We show that cDC are present in 
the naïve CNS and that targeted depletion of cDC reduces the incidence of disease, identifying 
cDC as critical for the initiation of EAE.   
 
Methods 
Mice.  C57Bl/6 and B6.Ly5.1 mice were from Charles River Laboratories.  Zbtb46-GFP, 
Zbtb46-DTR, CD11c-DTR, and 2D2 TCR transgenic mice were from the Jackson Laboratory.  
Both male and female mice, age 6-12 weeks, were used in experiments.  All mice were bred and 
maintained under specific pathogen-free conditions at the University of Michigan, and all animal 
experiments were performed in accordance with an IACUC-approved protocol at the University 
of Michigan. 
 
Induction and assessment of EAE.  For adoptive transfer, C57Bl/6 mice were subcutaneously 
immunized over the flanks with 100 µg MOG35-55 (Biosythesis) in complete Freund’s adjuvant 
(Difco).  At 10-14 days post-immunization, the draining lymph nodes (inguinal, brachial, and 
axillary) were collected and cultured for 96 hours in the presence of 50 ug/mL MOG35-55, 8 
ng/ml IL-23 (R&D Systems), 10 ng/ml IL-1α (Peprotech), and 10 µg/mL anti-IFNγ (Clone 
XMG1.2, BioXcell).  At the end of culture, CD4+ T cells were purified with CD4 positive 
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selection magnetic beads (Miltenyi), and 3-5x106 CD4+ T cells were transferred intraperitoneally 
into naïve recipients.  For active EAE, mice were immunized as before and injected with 300 ng 
of pertussis toxin (List Biological) on days 0 and 2.  EAE was assessed by a clinical score of 
disability: 1, limp tail; 2, hind-limb weakness; 3, partial hind-limb paralysis; 4, complete hind-
limb paralysis; and 5, moribund state.  Daily weight measurements were also taken. 
 
Cell Isolation.  Mice were anesthetized with isoflurane and perfused with PBS.  Meninges were 
isolated by removing the calvarium, placing the calvarium in a dish with PBS, and stripping the 
meninges from the inner surface.  The meninges tissue and loosely adherent cells released in the 
PBS were collected, pelleted, and incubated in a solution of HBSS with 1 mg/ml collagenase A 
(Roche) and 1 mg/ml DNase 1 (Sigma-Aldrich) for 20 minutes at 37°C.  The meninges were 
then passed through a 70-µm mesh filter to remove debris and generate a single cell suspension.  
The brain was removed from the skull, and the spinal cord was flushed from the spinal column 
with PBS.  The brain and spinal cord were homogenized with an 18G needle in the collagenase 
solution and incubated at 37°C for 20 minutes.  Mononuclear cells were separated from myelin 
with a 27% Percoll gradient (GE Healthcare).  Spleens were isolated and passed through a 70-
µm mesh filter to generate a single cell suspension.  Red blood cells from the spleen were lysed 
by a brief incubation in ACK lysis buffer (Quality Biological) followed by a wash in PBS. 
 
Cytokine production by DC subsets.  Mononuclear cells were isolated as above and cultured in 
complete RPMI with media, BFA (10 µg/mL), or BFA + LPS (6.7 µg/ml) for 4 hours.  At the 




Ex vivo cultures.  Mononuclear cells were isolated as above, and DC subsets, microglia, and B 
cells were flow sorted from the CNS and spleen according to the indicated surface markers.  For 
purification of naïve CD4+ T cells, lymph nodes and spleen were collected from naïve 2D2 TCR 
transgenic mice.  CD4+ T cells were enriched by positive selection with magnetic beads 
(Miltenyi), and naïve T cells were further purified by flow sorting for live CD4+CD44-CD62L+ T 
cells.  For purification of effector T cells, mononuclear cells from the CNS were flow sorted for 
live CD45+CD11b-CD3+CD4+MHC-II- T cells.  T cells were labeled with CFSE according the 
manufacturer’s instructions (ThermoFisher).  APC and T cells were co-cultured for 96 hours in 
complete RPMI at a ratio of 1:20 (typically 5,000 myeloid cells with 95,000 T cells) with media, 
myelin peptide (MOG35-55 peptide [Biosynthesis]), or myelin protein (MOG1-125 [Anaspec]).  At 
the end of culture, cells were cultured with PMA (50 ng/ml), ionomycin (2 µg/ml), and BFA (10 
µg/ml) for 4 hours to stimulate cytokine production.  Cells were collected and stained for 
activation by surface markers and cytokine production by intracellular staining. 
 
Flow cytometry.  Cells were labelled with fixable viability dye (eFluor506, eBioscience), 
blocked with anti-CD16/32 (Clone 2.4G2, hybridoma), and stained with fluorescent antibodies.  
Antibodies for CD62L (Clone MEL-14), FoxP3 (Clone MF23), and Zbtb46 (Clone U4-1374) 
were obtained from BD Biosciences.  Antibodies for CD26 (Clone H194-112), CD88 (Clone 
20/70), and PDL1 (Clone 10F.9G2) were obtained from Biolegend.  The following antibodies 
were obtained from eBioscience: CD3 (Clone 145-2C11), CD4 (Clones RM4-5, GK1.5), CD11b 
(Clone M1/70), CD11c (Clone N418), CD19 (Clone MB19-1), CD40 (Clone HM40-3), CD44 
(Clone IM7), CD45 (Clone 30-F11), CD45.1 (Clone A20), CD45.2 (Clone 104), CD80 (Clone 
16-10A1), CD86 (Clone GL1), GM-CSF (Clone MP1-22E9), IFNγ (Clone XMG1.2), IL-10 
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(Clone JES5-16E3), IL-12p35 (Clone 4D10p35), IL-12p40 (Clone C17.8), IL-17 (Clone 
eBio17B7), IL-23p19 (Clone fc23cpg), MHC-II (Clone M5/114.15.2), NOS2 (Clone CXNFT).  
Isotype control antibodies were matched for each.  Antibodies and isotype controls were 
conjugated to FITC, PE, PeCy7, APC, APC-Cy7, PerCP-Cy5.5, PerCP-eFluor710, PE/Dazzle 
594, eFluor450, eFluor660, AlexaFluor 647, or AlexaFluor 700.  Arginase was stained with 
FITC-conjugated antibody (IC5868F, R&D Systems) or with unconjugated antibody (AF5858, 
R&D Systems) and an AlexaFluor 647-conjugated donkey anti-sheep secondary (ThermoFisher).  
For intracellular staining of cytokines and enzymes, cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.5% saponin, and stained with fluorescent antibodies.  For intracellular 
staining of Zbtb46, cells were fixed and permeabilized with the Transcription Factor Buffer Set 
(BD Pharmingen).  Data was acquired using a FACSCanto II flow cytometer or FACSAria III 
flow sorter (BD Biosciences) and analyzed with FlowJo software (Treestar).  Cells were sorted 
with a FACSAria III flow sorter (BD Biosciences).  
 
 
Nanostring gene expression analysis.  Sorted cells were resuspended in RLT buffer, and cell 
lysates were directly analyzed for expression of 750 immune-related genes with the nCounter 
PanCancer Immune Panel (Nanostring Technologies).  Data was processed using the nSolver 
Analysis Software by normalization to the geometric mean of positive controls and housekeeping 
genes.  R was used to perform paired Student’s t-tests and calculate Benjamini & Hochberg’s 




Myelin phagocytosis.  Myelin was purified from naïve mice as previous144 and labelled with 
pHrodo Red succinimidyl ester (ThermoFisher) according the manufacturer’s instructions.  
Mononuclear cells from the CNS were resuspended in complete RPMI, plated in a flat bottom 
96-well plate, and cultured overnight with 1-5 µg of myelin per well.  Unlabelled myelin was 
used as a control.  Cells were collected by scraping, and pHrodo uptake was analyzed by 
fluorescence on a FACS Aria III cytometer.   
 
Bone marrow chimeras.  B6.Ly5.1 (CD45.1+) congenic hosts were lethally irradiated with 1300 
Rad split into two doses and reconstituted by tail vein injection of 4x106 CD45.2+ bone marrow 
cells from WT, CD11c-DTR, or Zbtb6-DTR donors.  Mice were allowed to reconstitute for 6 
weeks prior to use.   
 
DT Ablation.  Diphtheria toxin (Sigma) was administered in two stages.  Three daily doses of 1 
µg/20g mouse (50 µg/kg) in 200 µl of PBS were given i.p. prior to the assessment of DC 
depletion or to the induction of EAE.  Daily doses of 100ng/20g mouse (500 ng/kg) in 200 µl of 
PBS were given i.p. starting on the day of adoptive transfer and continuing until the end of the 
experiment. 
 
Statistics.  Statistical analysis was performed using paired or un-paired, 2-tailed Student’s t test, 






cDC are present in the CNS during EAE 
We began by investigating what myeloid cell subsets are present in the CNS during EAE.  
Disease was induced by adoptive transfer of myelin-primed Th17 cells, and mononuclear cells 
were isolated from the brain and spinal cord at peak disease.  Among MHCII+ antigen presenting 
cells, we identified multiple myeloid populations including CD45intCD11bint microglia, 
CD45+CD11b+CD11c- macrophages, and CD45+CD11c+ dendritic cells (DC) in the brain (Figure 
3.1A).  Similar results were observed in the spinal cord.  The DC population included both 
CD26+CD88- conventional DC (cDC) and CD88+CD26- monocyte-derived DC (moDC).   The 
macrophage and microglial populations expressed CD88 but not CD26.  Plasmacytoid 
DCs(pDC) also express CD26; however, the majority of pDC were MHCII- and contributed <5% 
of the MHCII+CD26+ population in the CNS during EAE (Supplemental Fig 3.1).  To confirm 
the identities of the DC populations, we performed transcriptional profiling of the CNS-derived 
CD26+ and CD88+ DC subsets (Figure 3.1B).  The CD26+ population expressed several core 
cDC transcripts recently identified by the ImmGen Project145, including Amica1, CCR7, and Kit, 
while the CD88+ population expressed several markers found on monocyte-derived cells 




Figure 3.1 – Expression of CD26 and Zbtb46 identifies cDC in the CNS in EAE. 
EAE was induced by adoptive transfer of WT myelin-primed Th17 cells.  (A) Gating of MHCII+ myeloid 
populations in the brain at the peak of adoptive EAE.  Numbers show percentage of parent population, as indicated 
above each plot.  (B) MHCII+CD11c+ CD26+ or CD88+ were purified by flow sorting, and gene expression was 
measured Nanostring nCounter analysis.  P value determined by paired, 2-tailed Student’s t test.  Genes with a false 
discovery rate (FDR) < 0.10 are identified in the heatmaps. (C, D) Expression of Zbtb46 by (C) flow cytometry or 
(D) with the Zbtb46gfp/+ reporter in MHCII+CD11c+ CD26+ and CD88+ cells from the brain at the peak of adoptive 
EAE. The shaded grey histogram is the (C) isotype or (D) non-reporter control. (E) Identification of Zbtb46-
expressing cells in the brain during adoptive EAE using the Zbtb46gfp/+ reporter.  Numbers show percentage of 




Zbtb46 was recently identified as a specific marker of cDC, so we assayed expression of 
Zbtb46 in the DC subsets by flow cytometry.  We identified Zbtb46 expression by CD26+ cDC 
but not CD88+ moDC in the brain during EAE (Figure 3.1C).  A Zbtb46-GFP reporter mouse has 
also been generated, and we confirmed reporter expression in CD26+ cDC but not in CD88+ 
moDC (Figure 3.1D).  A portion of the CD26 population was GFPlo; this may reflect the small 
pDC population or weak expression of the reporter.   We next analyzed all GFP+ cells in the 
CNS during EAE.  Both CD45+ hematopoietic and CD45- non-hematopoietic cells were labelled.  
The CD45- population may include endothelial cells84, but within the CD45+ population, reporter 
expression was enriched in CD26+ cDC.  These data confirm the identity of the CD26+ cells as 
cDCs which are present in the CNS during EAE. 
 
cDC but not moDC are competent antigen presenting cells 
We next questioned what roles cDC and moDC may play in disease.  Dendritic cells are 
professional antigen presenting cells, so we first investigated the antigen presenting capacity of 
the DC subsets.  We sorted MHCII+CD11c+ CD88+ moDCs and CD26+ cDC from the CNS at 
the peak of disease and co-cultured the cells ex vivo with naïve CD4+ 2D2 T cells, which have a 
T cell receptor specific for the MOG35-55 peptide
149.  cDC cultured with T cells and MOG35-55 
peptide promoted high levels of proliferation while moDC did not (Figure 3.2A).  T cells co-
cultured with cDC also expressed higher levels of the activation marker CD44 (Figure 3.2A) and 
the cytokines IFNγ and GM-CSF (Figure 3.2B).  No IL-17 or FoxP3 were detected (data not 
shown).  Similar results were obtained with cDC and moDC sorted from the spleen (data not 
shown).  Peptide and protein may be processed and loaded on MHCII through different 
pathways150, so we also assessed presentation of the MOG1-125 protein.  cDC were again superior 
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to moDC in presentation of this antigen (Figure 3.2A-B).  This deficit was not antigen-specific as 
cDC also displayed a higher capacity to activate OVA-specific OT-II cells151 when cultured with 
both OVA peptide and ovalbumin protein (data not shown).   
 
 
Figure 3.2 – Myelin-specific T cells are activated in co-culture with cDC but not moDC. 
EAE was induced by active immunization with myelin peptide, and immune cells were isolated from the CNS at 
peak disease.  CD26+ or CD88+ DC (CD45+MHCII+CD11c+) were purified by flow sorting and co-cultured with 
MOG-reactive T cells in the presence of myelin peptide (MOG35-55) or myelin protein (MOG1-125).  (A,B) DC 
subsets were co-cultured with CD44-CD62L+CD4+ T cells from naïve 2D2 TCR transgenic mice. (A) T cell 
proliferation was measured by CFSE dilution, and T cell activation was measured by CD44 expression, represented 
as a % of total CD4+ T cells.  (B) T cell cytokine production was measured by intracellular flow cytometry and 
represented as a % of total CD4+ T cells. (C) DC subsets were co-cultured with CD4+ T cells isolated from the CNS 
of actively immunized WT mice at the peak of EAE.  T cell proliferation and activation are shown before.  
Connected dots indicate paired samples from the same mouse.  *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 




While most T cells in lymphoid organs are naive, CD4+ T cells in the CNS during EAE 
are CD44hi effector cells.  To better reconstitute the immune synapse in the CNS during EAE, we 
next used effector T cells sorted from the CNS during EAE.  cDC induced proliferation of 
effector T cells while moDC did not (Figure 3.2C).  The effector T cells retained high expression 
of CD44 in both cultures.  Notably, this proliferation of effector T cells did not absolutely require 
the addition of exogenous antigen but could be enhanced by the addition of MOG peptide, 
suggesting the cDC acquired sufficient antigen in vivo to activate the effector T cells.  This is in 
contrast to activation of naïve T cells, which required the addition of exogenous peptide or 
protein.  Together, these data demonstrate that cDC but not moDC are proficient at activating 
myelin-specific T cells.   
Microglia and B cells may also express MHCII and act as APCs within the CNS, so we 
performed similar assays on these subsets.  We compared B cells derived from the CNS and the 
spleen, and we found that both were capable of activating naïve myelin-specific T cells when 
cultured with MOG peptide but not with MOG protein (Supplemental Fig 3.2A).  CNS-derived B 
cells were also capable of inducing effector T cell proliferation with and without exogenous 
antigen (Supplemental Fig 3.2B).  In contrast, MHCII+CD45intCD11bint microglia were deficient 
in promoting proliferation of either naïve or effector T cells (Supplemental Fig 3.2C-D).  This 
identifies B cells but not microglia as additional candidate APC in EAE.  However for the given 
study, we chose to focus on discriminating the DC subsets. 
 
cDC express higher levels of co-stimulatory markers 
We next investigated the reason for differential T cell activation between cDC and 
moDC.  Naïve T cells activation is commonly broken into three ‘signals’ derived from the 
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APC152.  Signal 1 is the presentation of antigen on MHC-II that is recognized by the T cell 
receptor.  Signal 2 is co-stimulation through ligands and receptors on the APC and T cell.  Signal 
3 is cytokine release by the APC which influences the differentiation of the T cell.  We 
investigated each signal in sequence. 
First, we explored antigen presentation.  DC were MHCII+CD11c+ by definition, so we 
analyzed the level of expression of MHCII by mean fluorescence intensity (MFI).  Two MHCII+ 
populations were noted within the CD26+ cDC subset: CD11chiMHCII+ and CD11cintMHCII++ 
(Figure 3.3A).  The CD26+MHCII+ population expressed similar levels of MHCII as the CD88+, 
but MHCII expression was elevated among CD26+MHCII++ population.  
Second, we investigated expression of co-stimulatory markers – CD40, CD80, CD86, and 
PDL1.  CD40, CD80, and CD86 provide positive co-stimulation153.  Similar to MHCII, 
expression of these markers was commensurate between CD88+ moDC and CD26+MHCII+ cDC 
but elevated in CD26+MHCII++ cDC (Figure 3.3B).  CD86, in particular, was not detected on 
CD88+ moDC or CD26+MHCII+ cDC but was expressed by CD26+MHCII++ cDC.  Reduced 
MHCII and co-stimulatory receptor expression could explain the difference in antigen presenting 
capacity, so we compared the function of the CD26+MHCII++ population with the 
CD26+MHCII+ and CD88+ population.  There was no difference in T cell activation in co-culture 
with the CD26+MHCII+ and MHCII++ populations, and both CD26+ populations promoted more 
T cell activation than the CD88+ (data not shown).  Therefore, the difference in expression of 
these surface receptors does not explain the difference in antigen presenting capacity. 
The co-stimulatory receptor PDL1 provides a negative signal which can block T cell 
proliferation154.  All the DC subsets expressed PDL1, but in a pattern distinct from the positive 
co-stimulatory receptors, the CD88+ and CD26+MHCII++ subsets expressed higher levels 
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compared to the CD26+MHCII+ subset (Figure 3.3B).  As both CD88+ and CD26+ subsets 
express PDL1, it is also unlikely to explain the functional differences between these subsets.  
 
Figure 3.3 – cDC and moDC differ in expression of co-stimulatory molecules and cytokines. 
EAE was induced by adoptive transfer of WT myelin-primed Th17 cells, and mononuclear cells were isolated from 
the CNS at the peak of EAE.  (A) Gating of DC populations based on MHCII expression in the brain.  MHCII 
expression quantified by geometric mean fluorescence intensity (MFI).  (B) Representative expression of co-
stimulatory molecules on indicated DC subsets in the brain.  Quantified as geometric MFI. (C)  Cells from the CNS 
were cultured for 4hr with brefeldin A (BFA), and cytokine production was assessed by intracellular flow 
cytometry.  Dots plots of representative flow for each cytokine with the isotype control or staining of the indicated 
DC subsets.  Quantified as a % of the indicated DC population.  (D) Comparison of cells cultured ex vivo in media, 
BFA, or BFA+LPS.  Isotype also shown as reference for non-specific staining.  *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001, and n.s. = P>0.05, by paired, 2-tailed Student’s t test.  N=3-5 mice per group or condition.  All 




cDC and moDC have distinct patterns of cytokine expression 
Third, we measured cytokine production by the DC subsets.  Mononuclear cells from the 
CNS were cultured ex vivo in media alone, with Brefeldin A (BFA) to trap cytokines prior to 
secretion, or with BFA plus LPS to stimulate cytokine production.  The condition with BFA 
alone reflects continued cytokine production from the CNS microenvironment.  We observed 
distinct patterns of cytokine production among the DC subsets such that CD26+ cDC expressed 
IL-12p40 while CD88+ moDC expressed IL-23p19 and IL-10 (Figure 3.3C).  IL-12p40 is a 
subunit of both IL-12 and IL-23.  IL-12 is a heterodimer of IL-12p40 and IL-12p35155 and 
polarizes T cells toward IFNγ production and the Th1 phenotype156.  Production of IL-12p40 by 
the CD26+ cDC corresponds with the IFNγ production by the co-cultured T cells (Figure 3.2B).  
We attempted to measure expression of IL-12p35, the second subunit of IL-12, but were limited 
by available methods.  IL-23 is a heterodimer of IL-12p40 and IL-23p19157 and polarizes T cells 
toward IL-17 production and the Th17 phenotype158.  CD88+ moDC express IL-23p19 but, in the 
absence of IL-12p40, are unlikely to express the heterodimer IL-23, consistent with the absence 
of IL-17 production by the co-cultured T cells.  Instead, CD88+ moDC production of IL-10 may 
exert an anti-inflammatory influence on the inflammatory process.     
Next, we questioned whether the DC subsets may be stimulated to produce additional 
cytokines.  Stimulation increased expression of IL-12p40 by CD26+ cells and IL-10 by CD88+ 
cells but decreased expression of IL-23p19 by CD88+ cells.  Importantly, it did not alter the 
pattern of expression (Figure 3.3D).  CD26+ cDC expressed IL-12p40 but not IL-23p19 or IL-10.  
CD88+ moDC expressed IL-23p19 and IL-10 but not IL-12p40.   
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In summary, differences in these three signals alone do not appear sufficient to explain 
the differential capacity of CD26+ cDC to promote T cell activation compared to CD88+ moDC.  
Further study is necessary to elucidate this mechanism. 
 
moDC are superior phagocytes 
Having established CNS-derived cDC as superior antigen presenting cells, we questioned 
the role of moDC in disease.  Much has been made of myeloid cell polarizations – classical or 
alternative, M1 or M2, iNOS- or Arg1-expressing cells – and the influence of these polarizations 
on the quality of the immune response159.  We found expression of the markers iNOS and Arg1 
exclusively in CD88+ moDC in the CNS during EAE (Figure 3.4A). 
 
Figure 3.4 – moDC express iNOS and Arg1 and phagocytose myelin. 
(A) EAE was induced by active immunization with myelin peptide, and immune cells were isolated from the CNS at 
onset or peak disease. Expression of iNOS and Arg1 was determined by intracellular flow cytometry.  
MHCII+CD11c+ DC were colored based on iNOS or Arg1 expression (left panel) and shown in reference to CD88 
and CD26 expression (right panel). (B) EAE was induced by adoptive transfer of WT myelin-primed Th17 cells, and 
mononuclear cells were isolated from the CNS at the peak of EAE.  Cells were culture overnight with unlabelled or 
pHrodo-labelled purified myelin.  Phagocytosis measured as % pHrodo+ of the gated CD26+ or CD88+ DC 





The monocyte/macrophage lineage is also specialized in phagocytosis.  Myelin 
phagocytosis may be pathogenic if removed from axons54 or protective if clearing debris160.  We 
evaluated myelin phagocytosis ex vivo by isolating mononuclear cells from the CNS and 
culturing the cells overnight with pHrodo-labelled purified myelin, obtained from a naïve mouse.  
~55% of CD88+ moDC took up myelin compared to ~25% of cDC (Figure 3.4B).  Similar results 
were obtained when moDC and cDC populations were sorted and cultured independently (data 
not shown).  Phagocytosis was inhibited by the addition of cytochalasin D, demonstrating myelin 
uptake was an active process requiring actin polymerization161 (data not shown).  Though CD88+ 
moDC are deficient in antigen presentation, these results suggest roles for CD88+ moDC in 
modulation of the inflammatory milieu and in myelin phagocytosis.     
 
cDC are present in the naïve and expand in disease 
At the peak of EAE, the number of moDC dominate the number of cDC (Figure 3.1A); 
however, we questioned how this balance may change over the course of disease.  A Flt3-
dependent, radiosensitive DC population has been described in the meninges138,139, so we 
investigated the DC subsets in the naïve brain, skull meninges, and spinal cord.  There was a 
population of MHCII+CD45+ cells which included CD11b-CD11c- lymphoid cells, 
CD11b+CD11c- macrophages, and CD11c+ DCs (Figure 3.5A).  The DC population was 
predominantly CD26+CD88-, and this population was abundant in both the brain and skull 
meninges but low in the spinal cord.  To validate the identities of these subsets, we evaluated 
expression of the Zbtb46-GFP reporter.  Expression was restricted to the CD26+ subsets (Figure 
3.5B), confirming their classification as cDC.  Furthermore, we evaluated antigen presentation as 
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before and found that MHCII+CD11c+CD26+ cDC from the naïve CNS are capable of activating 
naïve, myelin-specific CD4+ T cells (Figure 3.5C). 
 
Figure 3.5 – cDC are present in the naïve CNS and increase during EAE. 
(A) Mononuclear cells were isolated from the naïve brain, meninges, and spinal cord and gated on all 
MHCII+CD45+ cells (left) or further gated on CD11c+ cells (right).  (B) Zbtb46gfp/+ reporter expression in 
MHCII+CD11c+ DC subsets in the naïve CNS.  (C).  MHCII+CD11c+CD26+ cDC were isolated from the naïve CNS 
and co-cultured with naïve 2D2 T cells.  Representative proliferation and activation are shown as a % of total CD4+ 
cells.  (D, E) Cells were isolated from the naive CNS or from the CNS at pre-clinical or peak adoptive EAE.  (D) 
Cell counts are shown for the DC subsets.  (E) DC populations are represented as a percent of total MHCII+CD11c+ 




We next compared these populations at preclinical and peak time points in the course of 
adoptive EAE.  Comparing the brain, meninges, and spinal cord, we observed different patterns.  
In the brain and spinal cord, CD26+ cDC expanded from naïve to preclinical to peak time points, 
but this expansion was dwarfed by the dramatic increase in the CD88+ moDC (Figure 3.5D).  As 
a result, CD88+ moDC were dominant in the brain and spinal cord at peak disease (Figure 3.5E).  
In contrast in the meninges, CD26+ cDC showed a greater increase in number compared to 
CD88+, so CD26+ cDC remained the dominant DC population at peak disease. 
 
cDC are critical for initiation of experimental autoimmune encephalomyelitis 
Given the antigen presenting capacity of cDC and their presence in the naïve CNS, we 
hypothesized that cDC are critical for initiating EAE.  To investigate the role of DCs in EAE, we 
used transgenic mice with DC-specific expression of the diphtheria toxin receptor – CD11c-
DTR162 and Zbtb46-DTR83.  CD11c-DTR depletes both cDC and moDC while Zbtb46-DTR 
specifically targets only cDC83.  Both mice have expression on non-hematopoietic cells and 
experience significant toxicity with repeated dosing; therefore, we generated bone marrow 
chimeras with WT recipients and DTR-expressing bone marrow.  In these mice, a single dose of 
DT is sufficient to deplete all the DC in the spleen; however, repeat dosing is necessary to 
deplete the DC populations within the CNS.  We optimized the DT dosing strategy to deplete 
DCs in the CNS prior to disease transfer and maintain depletion through the disease course.  
Following three doses of DT in the DTR chimeras, CD26+ cDC in the brain and meninges were 
reduced by over 50% in both chimeras (Figure 3.6A).  CD88+ moDC were also reduced in the 
CD11c-DTR chimeras; however, there was a trend toward increased CD88+ moDC in the 
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Zbtb46-DTR meninges.  The rarity of CD11c+ DC in the spinal cord limited analysis of this 
tissue.   
 
Figure 3.6 – Depleting cDC reduces the incidence of EAE. 
Bone marrow chimeras were generated with CD45.1+ recipients and CD45.2+ WT, CD11c-DTR, or Zbtb46-DTR 
donors.  (A) Counts of DC subsets from donor (CD45.2+) bone marrow in the brain and meninges following DT 
ablation in naïve chimeras.  (B) DC were ablated with DT as in A, and EAE was induced by adoptive transfer of WT 
myelin-primed Th17 cells.  Clinical scores, weights, and incidence are shown for the three groups.  (C) Clinical 
scores and weights for only the WT and Zbtb46-DTR which showed signs of disease.  *P<0.05 by 2-tailed Student’s 
t test.  N=3-5 mice per group or condition.  All values are mean ± SEM. 
 
To evaluate the role of the DC subsets in EAE, we depleted DC with three doses of DT 
prior to adoptive transfer of myelin-primed Th17 cells.  Daily DT doses at a reduced level were 
continued for the duration of the disease course.  We observed that depletion of both DC subsets 
in the CD11c-DTR mice completely blocked disease (Figure 3.6B).  Depleted mice showed no 
signs of paralysis and minimal weight loss.  Furthermore, depletion of the cDC subset alone with 
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the Zbtb46-DTR reduced the incidence of disease by half (40% vs 80%).  This heterogeneity in 
response may reflect inefficient DC depletion in some mice.  The mice that did develop disease 
had a similar day of onset, maximum score, and degree of weight loss compared with the WT 
mice (Figure 3.6C).  This data suggests a role for DC in EAE and highlight cDC as the critical 
cell for initiating adoptive transfer EAE. 
 
Discussion 
In this study, we identified cDC in the CNS during adoptive EAE.  Previous studies in 
EAE have attempted to discriminate moDC and cDC by expression of Ly6C141; however, Ly6C 
is down-regulated by moDC differentiation in tissues163.  We also found that some 
CD26+Zbtb46+ cDC in the CNS express intermediate levels of Ly6C (unpublished data), so 
Ly6Clo and Ly6Cint cells are thus a mixture of cDC and moDC.  These caveats limit the utility of 
Ly6C as a marker.  The application of CD88 and CD26 as markers of moDC and cDC, 
respectively, allows more rigorous discrimination of these subsets.  We further validated these 
markers for DC from the CNS by analysis of the cDC-specific transcription factor Zbtb46 and 
cDC-specific gene expression.  Several recent studies have sought to identify DC subset-specific 
transcriptomes and to identify novel DC subsets by gene expression in mouse and humans145,164–
166.  This includes further division of cDC into cDC1 and cDC2 subsets, specialized for 
activation of CD8+ or CD4+ T cells, respectively.  Several markers have been proposed to 
distinguish these subsets including CD8 and CD103 for cDC1 and CD4 and CD11b for cDC2167, 
but expression of these markers may vary by tissue and disease model.  Further study is 
necessary to elucidate the contribution of these subsequent DC divisions in EAE, and there is 
much still to learn about the functional implications of these subsets in disease. 
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 Myelin-specific T cells must encounter an MHCII+ hematopoietic cell to initiate EAE, 
but the identity of this initiating APC is still unknown.  Dendritic cells are a leading candidate as 
transfer of DC can induce EAE168 and promote myelin-specific T cell proliferation in the 
CNS169.  We observed that CNS-derived CD26+ cDC but CD88+ moDC were competent antigen 
presenting cells.  A similar distinction in function was observed for CD26+ cDC and CD88+ 
moDC from the lung78.  Still others have shown, comparing Ly6C- cDC and Ly6C+ moDC 
derived from the lymph nodes and spleen, that Ly6C- myeloid cells were more proficient at 
inducing T cell proliferation44,170.  In contrast, Ly6C+ promoted more production of cytokines 
including IL-17 and IFNγ.  Our data and these studies suggest a role for cDC in T cell activation.  
In support of this, depleting Zbtb46-expressing cells with Zbtb46-DTR mice83 or knocking out 
MHCII on Zbtb46-expressing cells86 limits T cell responses to immunization.  These data 
demonstrate cDC are critical for antigen-specific T cells responses and thus are a promising 
candidate for the initiating APC. 
B cells are another APC candidate, in particular given the success of B cell targeted 
therapies in MS171.  In animal studies, the role of B cells differs by strain and antigen.  Some B 
cell-deficient strains, such as B10.PL, SJLxB10.PL, and C57Bl/6, are susceptible to disease 
induced by immunization with myelin peptide172–177, suggesting B cells are dispensable.  
However, other B cells appear critical in other models such as C3H/Fej and C3H.SW strains178 
and in C57Bl/6 mice immunized with human MOG protein174.   Still other studies which 
depleted B cells using anti-CD20 therapy have demonstrated an exacerbated disease course if 
depleted early or an ameliorated disease course if depleted late179,180, suggesting stage specific 
pathogenic or regulatory roles for B cells.   
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Our studies demonstrate that CNS-derived B cells are capable of activating myelin-
specific T cells.  However in contrast to cDC, B cells activated naïve T cells with the addition of 
MOG35-55 peptide but not MOG1-125 protein.  This may be due to differences in the ability to 
acquire peptide versus protein antigen.  Protein antigen uptake by B cells is primarily mediated 
through the B cell receptor (BCR)181, so acquisition of myelin antigen would require myelin-
specific B cells.  The number of myelin-specific B cells may be limited early in EAE; therefore, 
few B cells would be capable of myelin protein acquisition and presentation.  In support of this, 
we found that CNS B cells failed to phagocytose pHrodo-labelled myelin (data not shown).  
Another study with TCR transgenic mice found that the incidence of spontaneous disease 
increased when mated to BCR transgenic mice174.  This suggests that BCR specificity could be a 
limiting factor in initiating EAE.  As for whether B cells are critical, additional research is 
necessary to clarify the role of B cells in MS and EAE. 
 pDC have also been proposed as APC in EAE.  We indeed found PDCA1+ pDC in the 
CNS during EAE but observed that the majority of the cells did not express MHCII.  Current 
evidence suggests the role of pDC in EAE differs at different stages of disease.  Depleting pDC 
in early EAE with anti-PDCA1 antibodies ameliorates EAE182–184, but treatment with anti-
PDCA1 during ongoing disease exacerbates disease severity183.  Furthermore, pDC from myelin-
primed lymph nodes can activate myelin-specific T cells but reducing MHCII expression on 
pDC and B cells exacerbated disease185.  These data suggest a potential dual role for pDC: 
pathogenic during priming of active disease but protective in ongoing disease.  Notably, pDC 
appear dispensable for the initiation of disease as depletion of pDC did not reduce the incidence 
of disease183.  
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  The initiating APC is likely to be present in the naïve CNS to present myelin antigens to 
T cells and trigger the neuroinflammatory response. One key site for this interaction is the 
meninges.  MHCII+ cells have been identified in the meninges134–136, but to date the lineage of 
the cells has been unclear.  Using specific markers, we demonstrate that the CD11c+ DC in the 
naïve CNS are cDC and that these cells are capable of activating myelin-specific T cells.  A 
recent study by Anandasabapathy et al139 also highlighted the presence of Flt3-dependent DC in 
the meninges and their capacity for antigen presentation.  Other have shown that CD11c+ DC in 
the meninges are closely associated with the large dural vessels136,138,186–188 and even present in 
CNS lymphatics189.  CD11c+ and MHCII+ DC in these areas can interact with T cells the within 
vessels and promote their extravasation141,190.  In a seminal two-photon imaging study, 
Bartholomaus et al191 recorded T cells interacting with phagocytes in the meninges in the spinal 
cord during EAE, and a follow-up study went further to demonstrate that T cells are activated in 
an antigen-specific manner by interaction with leptomeningeal APC192. 
The sum of our data and the available literature supports a role for cDC in the initiation 
of EAE, and yet the necessity for DC in EAE is controversial due to inconsistencies in depletion 
studies.  We found that CD11c-DTR mice are completely resistant to adoptive EAE.  Published 
studies with high dose or high frequency, and which demonstrated DC depletion within the CNS, 
also found an ameliorative effect140,141.  Those with low dose or low frequency, and which only 
evaluated DC depletion in the periphery, observed no difference44,143.  This suggests the 
variability may be due to incomplete DC depletion.   
An additional study by Yogev et al suggests that DC depletion exacerbates severity after 
peak EAE, suggesting a regulatory role for DC in late EAE142.  This finding is supported by 
Clarkson et al140 who also observed that depleting DC starting at the peak of EAE exacerbated 
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disease.  It is possible that DC may play different roles during the pre-clinical and peak stages.  
DC may be required as APC to initiate EAE but may play a regulatory role later in disease.  
Consistent with this, we observed PD-L1 expression on both the moDC and cDC from the CNS 
at peak disease which may inhibit T cell activation or regulate Treg induction142,154. 
Having shown the CD11c+ DC are required for the initiation of EAE, we further 
interrogated the role of cDC.  By specifically targeting cDC with Zbtb46-DTR mice, we showed 
that depletion of cDC alone is sufficient to reduce the incidence of adoptive EAE.  Together, our 
data demonstrate that cDC are potent APC, both in the naïve and diseased CNS, and are the 
critical APC for initiating adoptive EAE.  These results suggest that cDC may be an attractive 





Supplemental Figure 3.1 – pDC are present in the CNS during EAE but express low levels 
of MHCII. 
EAE was induced by adoptive transfer of WT myelin-primed Th17 cells, and mononuclear cells were isolated from 
the brain and spinal cord at peak EAE.  (A) pDC were identified in the brain by expression of PDCA1 and expressed 
CD26 but low levels of MHCII. (B) Gating and quantification of pDC as a percentage of 11c+MHCII+ total DC and 




Supplemental Figure 3.2 – B cells but not microglia are competent antigen presenting cells. 
EAE was induced by active immunization with myelin peptide, and immune cells were isolated from the CNS and 
spleen (SP) at peak disease.  B cells (MHCII+CD45+CD11b-CD11c-CD19+) and microglia 
(MHCII+CD45intCD11bint) were flow sorted and co-cultured with MOG-reactive T cells in the presence of myelin 
peptide (MOG35-55) or myelin protein (MOG1-125).  (A) B cells or (C) microglia were co-cultured with CD44-
CD62L+ CD4+ T cells from naïve 2D2 TCR transgenic mice. (B) B cells or (D) microglia were co-cultured with 
CD4+ T cells isolated from the CNS of actively immunized WT mice at the peak of EAE. T cell proliferation was 
measured by CFSE dilution, and T activation was measured by CD44 expression, represented as a % of total CD4+ 
T cells.  Data are representative of at least 2 experiments.  Connected dots indicate paired samples from the same 
mouse.  N=3-5 mice per group.   
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Chapter 4 – Discussion 
 
Despite significant advances in MS treatment over the past decade, several challenges 
remain.  First, the fundamental etiology of MS remains unknown, so there are not therapies 
which can block the disease.  Second, there are no therapies which can reverse the disability 
caused by MS.  Myeloid cells can perform both pathogenic and pro-regenerative functions; 
therefore, targeting myeloid cells is a promising strategy to address both therapeutic gaps in MS.  
Myeloid cells may initiate or perpetuate an inflammatory response, so inhibiting myeloid cells 
may prevent episodes of neuroinflammation.  Conversely, myeloid cells may regulate the 
inflammatory response and stimulate neuronal or glial regeneration, so enhancing myeloid cells 
may facilitate repair and recovery.  Development of myeloid cell-targeted therapies is limited by 
a fundamental lack of understanding of these dual roles in neuroinflammation.  Through this 
thesis work, we have sought to better understand the role of myeloid cells in CNS autoimmunity. 
 
Targeting Myeloid Cells – Prevent Neuroinflammation 
 Neuroinflammation is dependent on the interaction of myelin-specific CD4+ T cells with 
APC121,122.  We demonstrated that cDC are present in the naïve and capable of activating myelin-
specific T cells.  Therefore, depleting the cDC in the CNS or inhibiting their antigen presenting 
functions are possible strategies to block the development of neuroinflammation.  In support of 
this, we showed that depletion of cDC reduced the incidence of adoptive EAE.  Several 
important questions remain. 
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 We showed that moDC were poor APC, but this did not seem to be due to low expression 
of MHCII, costimulatory molecules, or cytokines.  It also did not appear to be due to antigen 
acquisition as moDC were more proficient at myelin phagocytosis.  The mechanism for the 
difference in APC capacity between moDC and cDC is still unresolved.  One possible 
explanation is that moDC are deficient at loading the antigen on MHCII.  cDC express the 
protein H2-DMβ2, a non-classical MHC molecule that interacts with MHCII to load antigenic 
peptides193, but moDC do not (Figure 4.1A).  In fact, every subset with demonstrated APC 
capacity (cDC, B cells) expressed H2-DMβ2, and those deficient in presentation did not (moDC, 
macrophages, microglia).  Further, expression of the H2-DMβ2 and other genes of the MHC loci 
is regulated by the transcription factor class II transactivator194.  We observed enhanced 
expression of CIITA in cDC compared to MHCII+ moDC, macrophages, or microglia (Figure 
4.1B).  Several isoforms of CIITA exist which display cell-type specific expression195,196.  We 
noted that the pIII isoform was specific to the cDC population while the pI isoform was 
expressed by the moDC and cDC and the pIV isoform was expressed by microglia.  B cells also 
express the pIII isoform of CIITA197, so this provides a possible mechanism regulating H2-
DMβ2 expression and APC capacity in the subsets which are competent APC.  Further 




Figure 4.1 – H2-DMβ2 and CIITA are expressed by cDC and B cells. 
(A) Expression of H2-DMβ2 by MHCII+ cell subsets isolated from the brain at the peak of EAE, gated as indicated.  
(B) Expression of total CIITA or specific CIITA isoforms driven by the promoters pI, pIII, or pIV.  Mononuclear 
cells were isolated from the CNS at the peak of EAE, and MHCII+ cells subsets were flow sorted as indicated.  
Expression was determined by RT-qPCR. Data represented as mean ± SEM 
 
We also observed that the numbers of both cDC and moDC increase during the course of 
EAE.  Another important question is from where do these cells come.  Since cDC are present in 
the naïve CNS and can be expanded by cytokines138,139, we hypothesize that cDC are 
predominantly derived from in situ proliferation.  In contrast, moDC, which are derived from 
peripheral monocytes, predominantly traffic from the periphery.  This nuance is significant 
because therapies that block trafficking to the CNS may then affect the moDC but not the cDC.  
In addition, we identified two populations of cDC: MHCII+ and MHCII++.  In lymphoid tissues, 
these represent resident and migratory cDC populations, respectively198.  Migratory MHCII++ 
cDC traffic from an inflammatory tissue to lymph nodes in a CCR7-dependent manner199.  We 
found that CNS-derived cDC, but not moDC, expressed CCR7 transcript, supporting the 
migratory potential for these cells.  CD11c+ have been identified in lymphatics within the 
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CNS189, and we would hypothesize that these are MHCII++ cDC.  Therapies which limit 
trafficking of the cDC in the lymphatics may be efficacious in inhibiting neuroinflammation.   
In summary, our data suggest multiple ways to block the function of cDC as APC, but 
further research is necessary to investigate these pathways. 
 
Targeting Myeloid Cells – Promote Repair 
 A complementary therapeutic strategy would be to promote repair of the CNS tissue.  
cDC perform a critical pathogenic role as APC, but the role of moDC and other monocyte-
derived myeloid cells is unclear.  Since inhibiting monocyte recruitment to the CNS blocks 
disease43,45, cells of the monocyte lineage must exert a pathologic function early in disease.  
However, the function of myeloid cells may change as disease evolves.  DC depletion early in 
EAE ameliorated disease, but some of the DC depletion studies found that DC depletion at peak 
exacerbates late disease140,142.  The proposed mechanism was that DC express PD-L1 and 
promote Tregs which suppress the ongoing inflammatory process.  In the absence of DC, this 
regulation was absent and inflammation was exacerbated.  moDC express high levels of PD-L1 
and may thus be involved in the resolution of neuroinflammation. 
 The phenotype of myeloid cells changes during course of disease such that the cells 
express iNOS at onset but shift to express Arg1 at peak disease.  We found that expression of 
these markers was specific to monocyte-derived cells.  Arg1 is used as a marker of an anti-
inflammatory or pro-regenerative myeloid cell phenotype.  Arg1-expressing cells have been 
shown to promote oligodendrocyte differentiation through production of Activin A61, and we 
confirmed expression of Activin A in CNS myeloid cells (Figure 4.2A-B).  Activin A expression 
was higher in moDC compared with cDC and higher in Arg1+ myeloid cells compared with 
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Arg1-, highlighting the regenerative potential of these alternatively activated myeloid cells.  
Arg1-expressing cells may also promote axon growth by secretion of polyamines, the product of 
arginine metabolism by Arg130.  Degenerated myelin and myelin-associated glycoproteins inhibit 
neurite outgrowth in the CNS200.  Polyamines from Arg1-expressing cells overcome this 
inhibition31.  Further, myeloid cells may also clear this myelin debris by phagocytosis160,201, and 
we’ve shown that moDC are proficient myelin phagocytes.  These data demonstrate that myeloid 
cells can promote repair and remyelination of the damaged CNS. 
 
 
Figure 4.2 – Activin A is expressed by Arg1+ monocyte-derived cells in the CNS. 
(A) CD11b+ macrophage (11c-88+) and DC (11c+88+ moDC or 11c+26+ cDC) populations were sorted from CNS and 
spleen (SP) at the peak of EAE, and Activin A expression was determined by RT-qPCR. (B) Arg1- and Arg1+ 
macrophages (11c-) or DC (11c+) were sorted from the CNS of Arg1-eYFP reporter mice in late EAE and expression 
was measured by RT-qPCR.  Data represented as mean ± SEM.*P<0.05, **P<0.01 by paired, 2-tailed Student’s t 
test.   
 
iNOS and Arg1 are also functional enzymes which have an influence on the 
inflammatory response.  iNOS has been extensively studied in EAE, but the results are 
contradictory.  Inhibiting iNOS with a small molecule inhibitor ameliorates disease 202 while 
genetic deficiency in iNOS exacerbates disease 203.  We found that adoptive EAE was 
exacerbated in iNOS mice (Figure 4.3A), suggesting that iNOS may play a protective role in 
disease.  The reason for this discrepancy is unclear and requires further investigation204.  A 
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similar inconsistency has been observed for Arg1.  One report found that inhibiting Arg1 with 
the competitive inhibitor ABH delayed disease and reduced disease severity205; however, it is 
unclear whether this effect was mediated through inhibition of Arg1 in immune cells.  Using 
hematopoietic-specific knockout of Arg1 (Vav1-Cre x Arg1fl/fl), we showed that Arg1 is 
dispensable for the development of disease but that Arg1-deficient mice trend towards an 
enhanced severity of disease (Figure 4.3B).  This suggests a protective role for Arg1 as well.   
 
 
Figure 4.3 – Deficiency in either iNOS or Arg1 exacerbates EAE. 
(A) Clinical course of EAE induced by adoptive transfer of myelin-primed WT Th17 cells to WT or iNOS-deficient 
recipients.  (B) Clinical course of EAE induced by adoptive transfer of myelin-primed WT Th17 cells to mice with 
hematopoietic-specific Arg1 deficiency (Vav1-Cre x Arg1fl/fl) or littermate controls Arg1fl/fl).  All values are mean ± 
SEM.  Representative of at least two experiments. 
 
 Promoting Arg1 expression or the Arg1+ cell phenotype is a possible therapeutic strategy, 
but the factors which control this myeloid cell polarization in the CNS are not known.  We 
showed that Arg1 expression by CNS myeloid cells was independent of STAT6, distinguishing 
these cells from alternatively activated cells from other models206,207.  As an alternative, hypoxia 
inducible factor 1α (HIF1α) has also been described to promote Arg1 in myeloid cells119.  
Furthermore, CNS tissues become hypoxic during EAE208, providing a stimulus to promote 
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HIF1α stabilization209, and HIF1α protein is enriched in macrophages during EAE210.  We 
hypothesized that HIF1α may regulate Arg1 expression in the CNS.  To investigate the role of 
HIF1α in Arg1 expression in EAE, we generated mixed bone marrow chimeras using a knockout 
in which HIF1α is conditionally deleted in all hematopoietic cells (Vav1-Cre x HIF1αfl/fl = 
HIF1α-/-).  WT and HIF1α-deficient bone marrow reconstituted similar compositions of 
macrophages and dendritic cells (unpublished data); however at peak disease, the frequency of 
Arg1+ cells was reduced by >60% among HIF1α-deficient myeloid cells, compared with WT 
cells isolated from the same animal (Figure 4.4A).  At onset, iNOS is also significantly reduced 
(Figure 4.4B).  These data identify HIF1α as a critical regulator of Arg1 and iNOS in CNS-
infiltrating myeloid cells.  However, since HIF1α regulates both Arg1 and iNOS, the factor 
which promotes the conversion from iNOS to Arg1 expression in CNS myeloid cells remains to 






Figure 4.4 – Arg1 and iNOS expression in CNS myeloid cells is HIF1α-dependent. 
Mononuclear cells were isolated from the CNS of HIF1α-/- :WTWT mixed bone marrow chimeric mice at the 
peak of EAE (A) or the onset of EAE (B).  Representative flow and quantification of intracellular staining of Arg1 
and iNOS in WT or KO cells, gated on the CD45hiCD11b+Ly6G- population. Percentages are Arg1+ or iNOS+ cells 
among WT or KO CNS myeloid cells isolated from individual chimeric mice. Connected dots indicate cells derived 
from the same mouse.  *P<0.05, **P<0.01, ***P<0.001 and n.s. = P>0.05, by paired, 2-tailed Student’s t test.  Data 
are representative of at least 2 experiments.  N=3-5 mice per group.   
 
 In summary, monocyte-derived myeloid cells can inhibit inflammation, promote 
oligodendrocyte differentiation, and overcome axon growth inhibition.  However, the factors 
which control these functional programs are unclear and must be investigated further. 
 
Challenges in translating from EAE to MS 
Animal models are essential for studying human disease.  We have used EAE as a model 
of MS as it replicates key pathologic features of MS such as CNS-infiltration of immune cells 
and demyelinating lesions38.  However, there are limitations.  One of the significant differences 
between MS and EAE is the clinical course.  Individuals with MS most often follow at relapsing-
remitting course at onset and then convert to a progressive course later in disease7.  Most 
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available mouse models do not replicate this progression211.  C57Bl/6 mice follow a chronic 
course in which the mice maintain disability.  There is not remission but there is also no 
progression.  SJL mice follow a relapsing-remitting course but maintain their state of either 
remission or relapse long term.  There is no progression.  The closest model to the progressive 
course is the NOD mouse strain.  NOD mice are multigenic model of autoimmune diabetes212 
which follow a relapsing-remitting and subsequently progressive course following immunization 
with MOG35-55 peptide
213.  Unfortunately, wide use of this strain is limited due to the availability 
of genetic models on this background.    
These limitations are important as one interprets results from these models.  For example, 
we identified cDC are critical for initiating neuroinflammation in adoptive EAE in C57Bl/6 
mice.  Further study is necessary to determine if cDC are subsequently also required for the 
initiation of relapses.  This is therapeutically important as most MS patients begin treatment after 
having experience multiple episodes of demyelinating lesions214.    As another example, we 
showed that myeloid cells shift from expression of iNOS to Arg1 during course of adoptive EAE 
in C57Bl/6 mice.  Using the SJL model, we were also able to show that this shift occurs not only 
in the initial episode but also in subsequent relapses.  This strengthens our observation that 
myeloid cell polarizations shift with the evolution of neuroinflammation. 
Another significant challenge with using animal models is the differences in markers and 
gene expression between mice and humans.  Relevant to this work are differences in the 
expression of Arg1.  We found that Arg1 is widely expressed by CNS-infiltrating myeloid cells 
in EAE but expression is limited to perivascular mononuclear cells in humans (David Pitt, 
unpublished data).  This motivated our use of CD206 as an alternative activation marker. 
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The surface markers used to discriminate DC subsets in mouse and human are also 
different198.  CD11c expression is specific to DC in mice, but CD11c is also expressed by 
monocytes in humans, making it difficult to distinguish moDC with this marker215.  Furthermore, 
CD88 and CD26 have not been validated as markers of moDC or cDC in humans, so further 
study is necessary to determine if this distinction translates.  Zbtb46 has been shown in mouse 
and human DC on the transcript level in peripheral myeloid cells83,84, but no studies have used 
Zbtb46 to identify cDC in humans in situ.  Potential alternative markers which may be of use to 
discriminate cDC are specific to cDC subsets.  Mouse cDC continue to be subdivided into further 
subsets based on tissue location, inflammatory setting, and a host surface markers including 
CD8, CD103, CD11b, CD24, XCR1, CD172a, and more198.  However, human DC do not carry 
the same markers, so it is difficult to know how or if these subsets translate.  One functional 
division which appears consistent between mice and humans is between cDC which present 
antigen to CD8+ versus CD4+ T cells, identified as cDC1 and cDC2 respectively.  cDC1 express 
CD8 and/or CD103 in mice and express CD141 in humans; cDC2 express CD11b and/or CD4 in 
mice and express CD1c in humans.  Important to our work, CD11b+ cDC2 in mice are proficient 
at presenting antigen and activating CD4+ T cells163,216, and functional studies with CD1c+ cDC2 
from human peripheral blood demonstrate a similar capacity217.   
When possible, it is important corroborate observations from mouse models with human 
disease.  Many have undertaken studies of human immune cells from peripheral blood as a 
surrogate for CNS myeloid cells.  However, the value of this approach is limited as peripheral 
and CNS myeloid cells are fundamentally different.  cDC are exceedingly rare in the blood72, 
and it is not clear how the functions of the circulating cDC differ from tissue-resident cDC.  
moDC are not present in the blood but are specific to sites of inflammation.  As a proof of this 
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specificity, we observed that expression of Arg1 and iNOS was restricted to the CNS and not 
observed in the blood or other peripheral organs.  Some have attempted to overcome this by 
generating inflammatory moDC in vitro by culturing bone marrow or blood monocytes with 
GM-CSF218.  These cells can be stimulated to produce iNOS and Arg133, but unlike CNS-derived 
moDC, we found that these in vitro-generated moDC are competent antigen presenting cells 
(unpublished data), highlighting the fundamental problem of inferring properties of CNS 
myeloid cells from peripheral cells. 
Since functional studies on human CNS myeloid cells are not possible, 
immunohistochemistry provides a means to evaluate the presence of myeloid cell subsets in 
disease.  Having demonstrated that myeloid cells are heterogenous in EAE, we further validated 
this observation in MS lesions.  Having demonstrated that cDC are present in the CNS in naïve 
mice and during EAE, we are pursuing a collaboration to evaluate the presence of cDC in the 
human brain and meninges.  These studies are critical as we seek to translate our observations 
from EAE to MS.  
 
Conclusions 
The results presented in this dissertation advance our understanding of myeloid cell 
phenotypes and functions during MS and EAE.  We hope these studies will provide a foundation 
for the development of novel therapies that inhibit CNS autoimmunity and promote repair, 
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